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IN WITRO SCANNING SATURATION 
MUTAGENESIS OF PROTEINS 
The present application is a continuation-in-part of 
co-pending U.S. Provisional Patent Application Serial No. 
60/045,409 filed May 1, 1997. The entire text of the above 
referenced disclosure is specifically incorporated by refer 
ence herein without disclaimer. 
BACKGROUND OF THE INVENTION 
A. Field of the Invention 
The invention relates generally to the field of protein 
chemistry. More specifically, the invention relates to meth 
ods employed in the rapid generation of a large number of 
protein mutants. In one embodiment, mutant proteins are 
developed using PCR mutagenesis in combination with in 
Vitro transcription/translation. 
B. Related Art 
Understanding the chemical basis of protein Structure and 
function is one of the most important goals in biology. 
Studies over the last decade have attempted to determine 
how protein Structure dictates biological function. Site 
Specific mutagenesis has been a powerful tool in these 
Studies. Structure-guided, Site-specific mutagenesis repre 
Sents a powerful tool for the dissection and engineering of 
protein-ligand interactions (Wells, 1996; Braisted and Wells, 
1996). Typically, residues Suspected of contacting the ligand 
are subjected to a limited set of substitutions with other 
amino acids and their effects on binding are determined. 
Several studies, in particular with the T4 lysozyme 
(Matthews, 1995) and the human growth hormone (hGH)- 
hGH receptor complex (Wells and deVos, 1993), have 
combined information derived from crystal structures of a 
protein with Site-specific mutagenesis to analyze the role of 
contact residues with the ligand. Recently, the role of all the 
contact residues in the hCGH receptor protein was analyzed 
by replacement with alanines to investigate the effects of 
Side chain interactions without creating large-scale pertur 
bations in protein conformation. (Clackson and Wells, 1995; 
Cunningham et al., 1989). The results clearly show that out 
of the thirty-three amino acids in the hCGH receptor that are 
in van der Waals contact with the high affinity binding site 
of human growth hormone, two amino acids are responsible 
for over 75% of the binding energy. This result, which could 
not have been predicted on the basis of the crystal Structure 
of the complex alone, demonstrated that a very Small Subset 
of the residues at a protein-ligand interface can be respon 
Sible for the majority of binding energy. This study demon 
Strates the value of mutagenesis at a large number of 
residues within a protein. However, the study of hCGH was 
limited to the Substitution of alanine at a relatively small 
number of amino acids within the protein, and the Substi 
tution of functional residues with alanine, or any other Single 
amino acid, can give misleading results regarding their 
mechanistic importance (Warren et al., 1996). 
In addition to Site-specific mutagenesis, libraries gener 
ated by random mutagenesis have been employed to reveal 
principles of protein Structure. For example, cassette 
mutagenesis has been used to probe the “information con 
tent of polypeptide Sequences (Reidhaar-Olson and Sauer, 
1989; Davidson and Sauer, 1994; Davidson et al., 1995). 
These Studies involve the construction of polypeptide 
mutants composed of random combinations of Selected 
amino acids. The mutants are then analyzed for their thermal 
denaturation properties. This Study, utilizing existing tech 
nology to generate and characterize a relatively large num 












Thus, the comprehensive understanding of protein func 
tion typically involves the construction of hundreds, and 
possibly thousands of mutants. The logistics of Such large 
Scale mutagenesis experiments can be prohibitive. For each 
mutant protein, using current methodology, the appropriate 
gene construct must be made, a host organism must be 
transformed with the DNA, transformants must be selected 
and Screened for expression of the protein, and finally, the 
host cells must be grown to produce the protein. Using 
currently available methods, the production of a Single 
mutant polypeptide typically takes a minimum of two weeks 
of work by experienced personnel. While current methods 
for Site Specific mutagenesis may be acceptable in Structure 
guided Studies where only a few amino acid Substitutions 
may be of interest, it is impractical and prohibitively expen 
Sive when a hundred or more mutants need to be generated 
and analyzed. 
As a target for mutagenesis Studies, attention continues to 
be focused on antibodies, largely because they define a 
paradigm of high affinity protein binding and are among the 
most important classes of commercial protein molecules. 
Antibodies are nearly ideal reagents for the detection of 
analytes that are present in minute quantities in highly 
complex Samples, for example Soil Samples or biological 
fluids. However, because of inherent limitation of the 
immune System and of hybridoma technology there are 
many cases in which it has not been possible to produce 
monoclonal antibodies with the requisite affinity or Speci 
ficity for a particular application. Fortunately, recent 
advances in protein design and characterization techniques 
have paved the way for the engineering of antibodies with 
desired functions. 
At present, the engineering of antibodies that recognize 
and bind to antigens with higher affinity, are covalently 
linked to effector molecules Such as toxins, exhibit catalytic 
activity, or have been modified for better in vivo availability 
and Stability represents an exciting and rapidly evolving 
field (Morrison, 1992; Lillehoi and Malik 1993). Antibodies 
with tailored properties hold great promise as pharmaceuti 
cal reagents, for bioseparations and, perhaps most 
importantly, as diagnostic reagents in immunoassayS. 
Antigen binding is determined primarily, but not 
exclusively, by amino acid residues in the antibody hyper 
variable or complementarity determining regions (CDRS) I, 
II, and III of the heavy (H) and light (L) chains. There is 
evidence that the antigen binding site exhibits a fair degree 
of plasticity in that a number of amino acid Substitutions are 
tolerated and occasionally improve affinity (Chen et al., 
1995; Short et al., 1995). Studies have also demonstrated 
that the Second shell, as well as contact residues, can play an 
important role in Stabilizing the overall conformation of an 
antibody binding pocket and in turn affect the affinity and 
fine specificity of the antibody (Schildbach et al., 1993a, 
Schildbach et al., 1993b, Schildbach et al., 1994). 
One method used for the screening of antibody libraries is 
phage display (Short et al., 1995). In combination with 
mutagenesis techniques, phage display has been used to 
explore the effect of amino acid Substitutions on antigen 
affinity. Such large Scale Studies can provide important 
information concerning issues Such as: (i) the identity of 
residues that determine antigen affinity and specificity; (ii) 
what molecular interactions dominate the energetics of 
binding; (iii) the molecular basis of affinity maturation 
(Chen et al., 1995; Brown et al., 1996); and (iv) engineering 
of antibodies tailored for Specific applications in biotech 
nology (Harrison et al., 1996; Burton and Barbas, 1994). 
However, while phage display technology can Succeed in 
the identification of Sequence motifs that result in a high 
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affinity towards a desired antigen, this approach 
complements, and does not Substitute for, Site-specific 
mutagenesis. First, Since only the amino acid(s) that are 
compatible with high affinity binding can be identified in a 
biopanning experiment, it is not possible to examine the 
effect of other amino acid Substitutions that may result in 
Slightly lower affinity, Such as Second shell residues. Second, 
the polypeptide Sequences that can be isolated using phage 
display are limited by biological constraints. If a particular 
amino acid is incompatible with the biogenesis or the 
propagation of the bacteriophage particle then, the corre 
sponding clone cannot be isolated. And third, the isolation of 
antibody mutants exhibiting alterations in fine Specificity or 
small changes in affinity is technically difficult. These limi 
tations are particularly important for Saturation mutagenesis 
experiments where Specific residues are replaced with all 
nineteen amino acids. 
In recent years, there has been increased interest in the use 
of in vitro protein Synthesis to produce polypeptides for 
biochemical studies. Methods for in vitro translation to were 
used to generate C-terminal deletions in the B Subunit of 
tryptophan Synthase which were then employed to localize 
the epitope Sequences of a panel of monoclonal antibodies 
(Friquet et al., 1993). Mutants of the proliferating cell 
nuclear antigen (PCNA) have also been Synthesized using an 
in vitro to probe for Sequences important for the oligomer 
ization of the protein (Brand et al. 1994). In another 
application, a rabbit reticulocyte in vitro transcription/ 
translation system was used to identify antibody cINAS that 
were derived from transcripts with the correct VJ recombi 
nation and thus could give rise to the full length molecule 
(Nicholls et al., 1993). 
Thus far, in vitro protein Synthesis has not been employed 
extensively for protein engineering Studies. The main reason 
is that the amount of polypeptide obtained from in Vitro 
transcription/translation reactions generally is not adequate 
for rigorous biophysical analysis. However, the protein yield 
obtained by in Vitro Synthesis is more than adequate for 
determination of function, Such as ligand binding or cataly 
Sis. Protein yield also generally is adequate for general 
Studies Such as folding properties and expression levels. 
It is well appreciated that comprehensive information on 
the functional Significance and information content of a 
given residue of proteins in general, and antibodies in 
particular, can best be obtained by Saturation mutagenesis in 
which all 19 amino acid Substitutions are examined. A 
method which would allow for the facile site-saturation of a 
given protein, as well as being amenable to Screening 
methods, would provide a Significant advance in the discov 
ery process for protein-ligand interactions in general, and 
antibody-antigen interactions in particular. 
At present, while tools are available through which multi 
residue Saturation mutagenesis can be performed, the current 
methodology is impractical for the generation of a large 
number of mutants (Hilton et al., 1996). For each mutant 
protein, the appropriate gene construct must be made, the 
DNA must be transformed into a host organism, transfor 
mants need to be Selected and Screened for expression of the 
protein, the cells must be grown to produce the protein, and 
finally the recombinant mutant protein must be isolated. 
There have been only a handful of studies where one, or at 
most a few residues in an antibody have been Subjected to 
Saturation mutagenesis. Even in those Studies, only Some of 
the mutants were examined in detail (Ito et al., 1993; Chen 
et al., 1995; Brummel et al., 1993). Clearly, there remains a 
need for development of a System to allow hundreds, and 











be Studied in a Systematic fashion. In particular, there also 
remains a need for the development of a System for the 
generation and analysis of a large number of antibody 
mutantS. 
SUMMARY OF THE INVENTION 
It is, therefore, a goal of the present invention to provide 
compositions and methods relating to the generation and 
characterization of large numbers of protein mutants for the 
purpose of Selecting new proteins with novel and/or 
improved characteristics. Methods are provided for in vitro 
Scanning Saturation mutagenesis. The method of the present 
invention combines the generation of a DNA template, 
incorporating a large number of mutations, at predetermined 
Sites, by chemical or enzymatic processes, and the Subse 
quent generation of a new protein from the mutagenized 
DNA template using in vitro transcription/translation. 
The present invention provides a method of Selecting a 
polypeptide variant having analyte binding activity compris 
ing the Steps of providing a DNA segment encoding a 
polypeptide, or analyte-binding fragment thereof; generat 
ing a set of variant DNA segments, wherein the DNA 
Segments encode Substitution variants at Single residue of 
the polypeptide or analyte-binding fragment thereof; 
expressing each of the Substitution variants using in Vitro 
transcription/translation, Selecting the polypeptide variant 
based on analyte binding activity. In certain embodiments, 
the variant DNA segments further contain other substitution, 
deletion or insertion mutations not involving the Single 
residue. In particular embodiments the gene encodes an 
antibody. The set of variants DNA segments encodes each of 
nineteen possible amino acid Substitutions at the Single 
residue of the polypeptide or fragment. In a preferred aspect 
of the present invention the analyte binding activity is 
assessed by ELISA. 
In particular embodiments, the generating comprises a 
enzymatically Synthesized, site-direct mutagenesis. In pre 
ferred embodiments, the enzymatic Synthesis comprises 
PCR. In particular aspects the transcription/translation Step 
may employ a prokaryotic expression System. In other 
aspects, the gene is under the transcriptional control of a 
bacterial promoter. In preferred embodiments, the promoter 
may be T7, trc, tac, lipp-lac, trp, tet, lac, PBAD, phoA or PL 
or any promoter described in Table 1. 
The present invention further provides a method of iden 
tifying an antibody variant comprising the Steps of providing 
a DNA segment encoding a antibody, or antigen-binding 
fragment thereof; providing a set of primers that encode all 
nineteen amino acid variants at a single residue of the 
antibody or antigen-binding fragment thereof; performing 
PCR reactions on the DNA segment, using the set of 
primers, to generate a set of variant DNA segments encoding 
nineteen amino acid Substitution variants at the Single resi 
due of the antibody or antigen binding fragments thereof; 
expressing each of the Substitution variants using in Vitro 
transcription/translation, identifying the antibody variant by 
antigen binding activity. In one aspect, the primers are 
between about 10 and about 50 bases in length. In another 
aspect, the DNA segment encodes a Single-chain antibody. 
In other embodiments, the antibody may be a catalytic 
antibody, and the antibody variant further is identified by 
means of enzymatic activity. In certain other aspects it is 
contemplated that the antibody variant or antigen binding 
fragment thereof has a binding affinity for the antigen greater 
than the antibody. In yet further aspects it is contemplated 
that the antibody variant or antigen-binding fragment thereof 
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exhibits a lesser degree of croSS-reactivity with related 
antigen species than does the antibody. 
The present invention contemplates an antibody identified 
according to a method comprising the Steps of providing a 
DNA segment encoding a antibody, or antigen-binding frag 
ment thereof; providing a set of primers that encode all 
nineteen amino acid variants at a single residue of the 
antibody or antigen-binding fragment thereof, performing 
PCR reactions on the DNA segment, using the set of 
primers, to generate a set of variant DNA segments encoding 
nineteen amino acid Substitution variants at the Single resi 
due of the antibody or antigen binding fragments thereof, 
expressing each of the Substitution variants using in Vitro 
transcription/translation; identifying an antibody by antigen 
binding activity. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, Since various changes and modifi 
cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 
embodiments presented herein: 
FIG. 1. Structures of digoxin and the three analogs used 
in the present Studies. 
Points of difference compared to digoxin are indicated 
with the arrows. 
FIGS. 2A-J. Histograms of the ELISA data for the 
different mutant proteins binding to digoxin, digitoxin, 
digoxigenin, and Ouabain. FIG. 2A: Mutations of residue 
H:Tyr33. FIG. 2B: Mutations of residue H:ASn35. FIG. 2C: 
Mutations of residue H:TyrS0. FIG. 2D: Mutations of resi 
due H:Trp100. FIG. 2E: Mutations of residue L:Val94. FIG. 
2F: Mutations of residue L: Pro96. FIG. 2G: Mutations of 
residue H:Tyr47. FIG. 2H: Mutations of residue 
H:Met 100B. FIG. 2I: Mutations of residue H:Ser95. FIG. 2J: 
Mutations of residue L:ThrS1. The plotted values corre 
spond to the absorbance observed in ELISA measured at 405 
nm on a microplate autoreader when the ABTS reaction was 
Still in the linear range, a fact that was confirmed by taking 
Several time points per plate. For each cardiac glycoside 
being investigated (digoxin, digitoxin, digoxigenin, 
Ouabain) the absorbances for each mutant were linearly 
scaled to that of the wild-type scFv(Dig), which was 
assigned a value of 1.0, then plotted in the histograms. 
Wild-type scFV(Dig) was included on every ELISA plate to 
provide an internal calibration of the data. 
FIG. 3A and FIG. 3B. FIG. 3A Scheme for the overlap 
PCR production of mutant constructs t be used as templates 
for in vitro transcription-translation reactions. FIG. 3B 
Scheme showing how the gene constructs are used to make 
mutant SciFV(Dig) through in vitro transcription/translation 
followed by ELISA analysis. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
AS Stated above, there is a great need for improved 











Screening of variant polypeptides. The present invention 
addresses this need by providing, in one aspect, methods for 
the generation of a large number of mutations within a 
protein, and the Subsequent rapid assaying of mutants for 
appropriate characteristics. The principal underlying this 
technology is that by integrating DNA mutagenesis tech 
niques and in vitro transcription/translation, it is possible to 
generate and analyze large numbers of mutant proteins, 
resulting in about a ten-fold reduction in time over currently 
available techniques. The use of in Vitro techniques for 
transcription/translation of mutant polypeptides eliminates 
the need for many of the high cost, labor intensive cloning 
procedures currently used to express mutant proteins. 
In the present invention, the mutagenized DNA products 
are used directly as the template for in Vitro synthesis of the 
corresponding mutant proteins. Because of the high effi 
ciency with which all 19 amino acid substitutions can be 
generated at a Single residue, it is possible to perform 
Saturation mutagenesis on numerous residues of interest, 
either independently or in combination with other mutations 
within the protein. AS used herein, "complete Saturation” 
mutagenesis is defined as replacing a given amino acid 
within a protein, with the other 19 naturally-occurring amino 
acids. 
A. The Present Invention 
Using the appropriate oligonucleotide primers, PCR is 
used for the rapid synthesis of the DNA template containing 
one or more mutations in the binding protein gene. The 
protein gene is placed downstream of a T7 RNA polymerase 
promoter. Addition of T7 RNA polymerase and nucleosides 
results in synthesis of mRNA which is then translated in 
vitro by E. coli ribosomal (S30) extract, all in the same 
reaction. Of course, the T7 promoter and T7 RNA poly 
merase are only exemplary promoter/polymerase System, 
other promoters include, but are not limited, to those 
described in Table 1. For a comprehensive review of bac 
terial gene expression and bacterial promoters the skilled 
artisan is referred to Makrides (1996). Finally, aliquots from 
the translation mix are directly assayed for function by 
quantitative ELISA. The whole process of in vitro protein 
Synthesis and antigen binding assay by ELISA consists of a 
Series of mixing, incubation and washing Steps. All of these 
StepS are readily amenable to automation using laboratory 
robotic Stations. An example of a binding protein is an 
antibody. The present invention exemplifies in Vitro Scan 
ning mutagenesis using Single chain antibodies (ScPv) 
against cardiac glycosides, however, it is understood that 
any polypeptide that is able to bind to an analyte will be 
amenable to the present invention. 
TABLE 1. 
Promoters used for high level gene expression in E. coli. 
Promoter (source) Regulation Induction 
lac (E. coli) lacI, lacl IPTG 
lacI(TS), lac19(Ts) Thermal 
lacI(Ts) Thermal 





lpp (E. coli) 
phoA (E. coli) phoB (positive), phoR 
(negative) 
recA (E. coli) lex4 Nalidixic acid 
araBAD (E. coli) araC L-Arabinose 
proU (E. coli) 
cst-1 (E. coli) 
Osmolarity 
Glucose starvation 
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TABLE 1-continued 
Promoters used for high level gene expression in E. coli. 
Promoter (source) Regulation Induction 
tetA (E. coli) Tetracycline 
cada (E. coli) cadR pH 
nar (E. coli) fnir (FNR, NARL) Anaerobic 
conditions, 
nitrate ion 
tac, hybrid (E. coli) lacI, lacl IPTG 
lacid Thermal 
trc, hybrid (E. coli) lacI, lacl IPTG 
lacI(Ts), lacI(Ts) Thermal 
lipp-lac, hybrid (E. coli) lacI IPTG 
Pyn synthetic (E. coli) lacI, lacl IPTG 
Starvation promoters 
(E. coli) 
p1 (W) AcIts857 Thermal 
p-9G-50, mutant (W) Reduced 
temperature 
(<20° C.) 
CspA (E. coli) Reduced 
temperature 
(<20° C.) 
pr, pl. tandem (W) AcIts857 Thermal 
T7 (T7) AcIts857 Thermal 
T7-lac operator (T7) lac IPTG 
Wp, pr7, tandem (W, T7) WCIts857 Thermal, IPTG 
T3-lac operator (T3) ac IPTG 
T5-lac operator (T5) lacI, lacI IPTG 
T4 gene 32 (T4) T4 infection 
nprM-lac operator ac IPTG 
(Bacillus spp.) 
VHb (Vitreoscilla spp.) OXygen, 
cAMP-CAP 
Protein A (Staphylococcus 
aureus) 
lacI gene with single mutation, Gly-187 -> Ser (72). 
lacI gene with three mutations, Ala-241 -> Thr; Gly-265 -> Asp; and 
Ser-300 -> Asn (604). 
The constitutive lipp promoter (P) was converted into an inducible pro 
moter by insertion of the lacUV5 propmoter/operator region downstream 
of P. Thus expression occurs only in the presence of a lac inducer 
142). 
Wild-type lacI gene. 
cAMP-CAP, cyclic AMP-catabolite activator protein 
PCR is used to introduce the mutations and construct the 
complete ScFv genes. Once an interesting amino acid in the 
antibody binding pocket has been chosen, a Series of twenty 
one different PCR primers are ordered that are complemen 
tary to the antibody gene, centered around the amino acid of 
interest. Each primer is identical except for the codon of the 
chosen amino acid. E. coli preferred codons for the twenty 
different amino acids and a stop codon (as a control) are used 
in different PCR reactions. The twenty-one different gene 
fragments are then incorporated into complete ScFV genes 
using a Second Step of PCR, the So-called "overlapping” 
method. As a result, using only PCR, Sufficient quantities of 
all the required ScFV gene fragments are produced in 
twenty-one different Vials, each gene identical except of the 
codon of interest. All of the genetic machinery necessary for 
the coupled in vitro transcription-translation Step is present 
on the PCR products. 
Functional scFV's are produced from the PCR products 
using coupled in vitro transcription-translation reactions. In 
twenty-one Separate reactions, the PCR products are tran 
Scribed into messenger RNA, that is then translated into 
protein in the same reaction, the So-called “coupled' 
approach. A preferred embodiment uses the T7 promoter on 
the gene and thus T7 RNA polymerase to transcribe the 
message. The inventors used E. coli S30 ribosomal extracts 











the Significant advantage of eliminating the need to cap the 
message However, it is contemplated that mammalian or 
plant cell extracts could be used. The twenty-one different 
vials that started with ScFv genes assembled by PCR now 
contain Samples of the corresponding functional ScFVs. 
Importantly, the System is reproducible enough that very 
Similar levels of gene products are produced in each reac 
tion. Thus, no further manipulation or purification is 
required before the quantitative ELISA analysis. 
Without the need for further purification, the protein 
products from the coupled in vitro transcription-translation 
Step are analyzed quantitatively by ELISA. Both key aspects 
of ScFV binding can be quantitatively investigated using 
these ELISAS, namely affinity and specificity. Since the 
concentrations of ScFV are similar in each reaction, higher 
ELISA activity corresponds to higher scFV affinity, and vice 
Versa. Moreover, different antigen analogs may be used to 
check for binding specificity. Since multiple ELISAS can be 
run with the product of a single in vitro transcription 
translation reaction, desirable binding features of a particu 
lar mutant can be identified quickly and precisely. Thus, 
quantitative information is obtained for all the mutants, 
allowing for detailed Structure-function analyses. Most 
importantly, Since protein Structure and function cannot yet 
be predicted based on amino acid Sequence alone, Scanning 
Saturation mutagenesis provides the only feasible method to 
Systematically identify antibodies with desirable new prop 
erties. Therefore the present invention provides the only 
method to achieve Scanning Saturation mutagenesis in a fast, 
efficient and cost-effective manner. 
B. Proteins and Protein Structures of Interest 
Proteins generated by methods of the present invention 
comprise Virtually any amino acid Sequence as generated 
from a DNA template. Proteins may be composed of known 
wild-type Sequences or may contain one or more mutations 
or amino acid Substitutions within the amino acid Sequence. 
Proteins also may include one or more amino acid deriva 
tives within their Sequence. Each protein is Subject to further 
modification, according to the present invention, to intro 
duce or improve desirable characteristics. 
Representative mutant proteins contemplated by the 
present invention are Substitution mutants. Amino acids 
usually are grouped according to their side chains: Simple 
aliphatic side chains (e.g. glycine, alanine, Valine, leucine 
and isoleucine), aromatic side chains (e.g. phenylalanine, 
tryptophan, tyrosine, and histidine), oxygen and Sulfur con 
taining side chains (e.g. Serine, threonine, methionine and 
cysteine), Side chains containing carboxylic or amide groups 
(e.g. aspartic acid, glutamic acid, asparagine and glutamine), 
and Side chains containing strongly basic groups (e.g. lysine 
and arginine), and proline. Derivatives of amino acids are 
also contemplated. An amino acid derivative as used herein 
is any compound that contains within its structure the basic 
amino acid core of an a amino-Substituted carboxylic acid, 
with representative examples including aZaSerine, 
fluoroalanine, GABA, ornithine, norleucine and cycloSerine. 
These changes will require more detailed manipulations to 
accomplish. 
Certain amino acids may be Substituted for other amino 
acids in a protein Structure without appreciable loSS of 
interactive capacity with Structures Such as, for example, 
Substrate-binding regions. These changes are termed “con 
Servative' in the Sense that they preserve the Structural and, 
presumably, required functional qualities of the Starting 
molecule. Conservative amino acid Substitutions generally 
are based on the relative similarity of the amino acid 
Side-chain Substituents, for example, their hydrophobicity, 
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hydrophilicity, charge, size, and the like. An analysis of the 
size, shape and type of the amino acid Side-chain Substitu 
ents reveals that arginine, lysine and histidine are all posi 
tively charged residues; that alanine, glycine and Serine are 
all a similar size; and that phenylalanine, tryptophan and 
tyrosine all have a generally similar shape. Therefore, based 
upon these considerations, arginine, lysine and histidine, 
alanine, glycine and Serine; and phenylalanine, tryptophan 
and tyrosine, are defined herein as equivalent. 
In making Such changes, the hydropathic index of amino 
acids also may be considered. Each amino acid has been 
assigned a hydropathic indeX on the basis of their hydro 
phobicity and charge characteristics, these are: isoleucine 
(+4.5); Valine (+4.2); leucine (+3.8); phenylalanine (+2.8); 
cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); 
glycine (-0.4); threonine (-0.7); Serine (-0.8); tryptophan 
(-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); 
glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); aspar 
agine (-3.5); lysine (-3.9); and arginine (-4.5). 
The importance of the hydropathic amino acid indeX in 
conferring interactive biological function on a protein is 
generally understood in the art (Kyte & Doolittle, 1982). It 
is known that certain amino acids may be Substituted for 
other amino acids having a similar hydropathic index or 
Score and Still retain a similar biological activity. In making 
changes based upon the hydropathic index, the Substitution 
of amino acids whose hydropathic indices are within t2 is 
preferred, those which are within t1 are particularly 
preferred, and those within t0.5 are even more particularly 
preferred. 
It also is understood in the art that the Substitution of like 
amino acids can be made effectively on the basis of 
hydrophilicity, particularly where the polypeptide created is 
intended for use in immunological embodiments, as in the 
present case. U.S. Pat. No. 4,554,101, incorporated herein 
by reference, States that the greatest local average hydro 
philicity of a protein, as governed by the hydrophilicity of its 
adjacent amino acids, correlates with its immunogenicity 
and antigenicity, i.e., with a biological property of the 
protein. 
As detailed in U.S. Pat. No. 4,554,101, the following 
hydrophilicity values have been assigned to amino acid 
residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0t1); 
glutamate (+3.0t1); Serine (+0.3); asparagine (+0.2); 
glutamine (+0.2); glycine (O); threonine (-0.4); proline 
(-0.5+1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 
methionine (-1.3); Valine (-1.5); leucine (-1.8); isoleucine 
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). 
In making changes based upon similar hydrophilicity 
values, the Substitution of amino acids whose hydrophilicity 
values are within +2 is preferred, those which are within +1 
are particularly preferred, and those within t0.5 are even 
more particularly preferred. 
Numerous scientific publications have been devoted to the 
prediction of Secondary Structure, and to the identification of 
epitopes, from analyses of amino acid sequences (Chou & 
Fasman, 1974a,b; 1978a,b; 1979). Any of these may be used, 
if desired, to supplement the teachings of Hopp in U.S. Pat. 
No. 4,554,101. Moreover, computer programs are currently 
available to assist with predicting antigenic portions and 
epitopic core regions of proteins. Examples include those 
programs based upon the Jameson-Wolf analysis (Jameson 
& Wolf, 1988; Wolf et al., 1988), the program PepPlot(R) 
(Brutlag et al., 1990; Weinberger et al., 1985), and other new 












Two designations for amino acids are used interchange 
ably throughout this application, as is common practice in 
the art. Alanine=Ala (A); Arginine=Arg (R); Aspartate=ASp 
(D), Asparagine=ASn (N), Cysteine=CyS (C); Glutamate= 
Glu (E); Glutamine=Gln (Q); Glycine=Gly (G); Histidine= 
His (H); Isoleucine=Ile (I); Leucine=Leu (L); Lysine=Lys 
(K); Methionine=Met (M); Phenylalanine=Phe (F); Proline= 
Pro (P); Serine=Ser (S); Threonine=Thr (T); Tryptophan= 
Trp (W); Tyrosine=Tyr (Y); Valine=Val (V). 
Because of the degeneracy of the genetic code, a given 
polypeptide may be encoded by many nucleic acids. For 
example, four different three-base codons encode the amino 
acids alanine, glycine, proline, threonine and Valine, while 
Six different codons encode arginine, leucine and Serine. 
Only methionine and tryptophan are encoded by a single 
codon. A table of amino acids and the corresponding codons 
is presented herein (Table 2) for use in such embodiments. 
TABLE 2 
Amino Acids Codons 
Alanine Ala A GCA GCC GCG GCU 
Cysteine Cys C UGC UGU 
Aspartic acid Asp D GAC GAU 
Glutamic acid Glu E GAA GAG 
Phenylalanine Phe F UUC UUU 
Glycine Gly G GGA GGC GGG GGU 
Histidine His H CAC CAU 
Isoleucine Ile I AUA AUC AUU 
Lysine Lys K AAA AAG 
Leucine Leu L UUA UUG CUA CUC CUG CUU 
Methionine Met M AUG 
Asparagine Asn N AAC AAU 
Proline Pro P CCA CCC CCG CCU 
Glutamine Glin O CAA CAG 
Arginine Arg R AGA AGG CGA CGC CGG CGU 
Serine Ser S AGC AGU UCA UCC UCG UCU 
Threonine Thir T ACA ACC ACG ACU 
Valine Val V GUA GUC GUG GUU 
Tryptophan Trp W UGG 
Tyrosine Tyr Y UAC UAU 
In order to generate any nucleic acid encoding a specific 
polypeptide, one need only refer to the preceding codon 
table. Substitution of the natural codon with any codon 
encoding the same amino acid will result in a distinct nucleic 
acid that encodes a given polypeptide or a variant thereof. AS 
a practical matter, this can be accomplished by the in Vitro 
mutagenesis methodology described herein. 
The preceding observations regarding codon Selection, 
Site-directed mutagenesis and chemical Synthesis apply with 
equal force to the discussion of Substitutional mutants in the 
Section of peptides. Normally, Substitutional mutants are 
generated by Site-directed changes in the nucleic acid 
designed to alter one or more codons of the coding Sequence. 
Although the present invention is applicable to any pro 
tein Sequence, proteins which have a convenient assay for 
activity Such as catalytic activity or ligand binding are 
preferred. AS used herein, a ligand is any molecule which 
binds Specifically to a larger one, Such as Small molecule 
binding to a protein. Representative examples of target 
interactions include catalysis, enzyme-Substrate 
interactions, protein-nucleic acid interactions, receptor 
ligand interactions, protein-metal interactions and antibody 
antigen interactions. Representative target proteins include 
enzymes, antibodies, cytokines, receptors, DNA binding 
proteins, chelating agents, and hormones. 
In a specific embodiment, an antibody or an antibody 
fragment is the target protein. The read-out for antibody 
function generally is binding to an antigen or antigen 
variant. This aspect of the invention is discussed in greater 
US 6, 180,341 B1 
11 
detail below. As used herein, the term “antibody' or “anti 
body fragment' is used to refer to any immunologic binding 
agent Such as IgG, IgM, IgA, Ig) and IgE, or any antibody 
like molecule that has an antigen binding region, and 
includes antibody fragments Such as Fab', Fab, F(ab'), 
Single domain antibodies (DABs), Fv, ScFv (single chain 
Fv), and the like. The techniques for preparing and using 
various antibody-based constructs and fragments thereof are 
well known in the art. 
An important aspect of the present invention is the 
identification of residues that play, or are likely to play, a role 
in the interaction of interest (e.g., antigen-antibody 
interaction, metal chelation, receptor binding, Substrate 
binding, etc.). Two primary approaches are envisioned for 
this identification. First, one may rely on crystal Structures of 
the protein of interest. This information, possibly in com 
bination with a structural analysis of the natural Substrate 
and any enzymatically altered form, should predict the key 
contact points in the polypeptide. The crystal Structure for a 
large number of proteins now exists and can be accessed 
through the Brookhaven Protein Database. 
Second, as more and more protein Sequences become 
available through Sequencing efforts, the ability to predict 
critical residues in antibodies, enzymes and other active 
proteins increases dramatically. Over and over, motifs are 
appearing that Serve the same or Similar functions in distinct 
polypeptides. Thus, it will become easier and easier to 
predict, without any actual experimentation, those residues 
that contribute to a protein's activity. 
C. Antibody Constructs 
Antibody and Antibody Fragment Constructs 
Any antibody or antibody fragment may be used accord 
ing to the present invention. However, the preferred con 
Struct comprises a single chain antibody format, since no 
chain association event must take place following the trans 
lation. This facilitates the in vitro system for transcription/ 
translation, as discussed and exemplified below. “Antibody” 
or “antibody fragment” refers to any immunologic binding 
agent Such as IgG, IgM, IgA, Ig) and IgE or any antibody 
like molecule that has an antigen binding region, and 
includes antibody fragments Such as Fab', Fab, F(ab'), 
single domain antibodies (DABs), Fv, scFv (single chain Fv) 
and the like. The techniques for preparing and using various 
antibody-based constructs and fragments are well known in 
the art. 
The specificity of an antibody is determined by the 
complementarity determining regions (CDRS) within the 
light chain variable regions (V) and heavy chain variable 
regions (V). The F., fragment of an antibody, which is 
about one-third the size of a complete antibody contains the 
heavy and light chain variable regions, the complete light 
chain constant region and a portion of the heavy chain 
constant region. F, molecules are stable and associate well 
due to the contribution of the constant region Sequences. 
However, the yield of functional F expressed in bacterial 
systems is lower than that of the smaller F fragment which 
contains only the variable regions of the heavy and light 
chains. The F fragment is the Smallest portion of an 
antibody that Still retains a functional antigen binding site. 
The F fragment has the same binding properties as the F., 
however without the stability conferred by the constant 
regions, the two chains of the F can dissociate relatively 
easily in dilute conditions. 
To overcome this problem, V and V, regions may be 
fused via a polypeptide linker (Huston et al., 1991) to 
Stabilize the antigen binding site. This single polypeptide F. 
fragment is known as a single chain antibody (ScP). The V, 
and V, can be arranged with either domain first. The linker 
joins the carboxy terminus of the first chain to the amino 












While the present invention has been illustrated with the 
mutagenesis and in vitro transcription/translation of Single 
chain F, one of Skill in the art will recognize that heavy or 
light chain F or F, fragments may also be used with this 
System. A heavy or light chain can be mutagenized followed 
by the addition of the complementary chain to the Solution. 
The two chains are then allowed to combine and form a 
functional antibody fragment. Addition of random non 
Specific light or heavy chain Sequences allows for the 
production of a combinatorial System to generate a library of 
diverse members. 
Antibody and Antibody Fragment Gene Isolation 
To accomplish construction of antibodies and antibody 
fragments, the encoding genes are isolated and identified. 
The genes can be modified to permit cloning into an expres 
Sion vector or an in Vitro transcription/translation. Although 
methods can be used Such as probing the DNA for V and 
V, from hybridoma cDNA (Maniatis et al., 1982) or con 
Structing a synthetic gene for V and V. (Barbas et al., 
1992), a convenient mode is to use template directed meth 
ods to amplify the antibody Sequences. A diverse population 
of antibody genes can be amplified from a template Sample 
by designing primers to the conserved Sequences at the 3' 
and 5' ends of the variable region known as the framework 
or to the constant regions of the antibody (Iverson et al., 
1989). Within the primers, restriction sites can be placed to 
facilitate cloning into an expression vector. By directing the 
primers to these conserved regions, the diversity of the 
antibody population is maintained to allow for the construc 
tion of diverse libraries. The Specific Species and class of 
antibody can be defined by the selection of the primer 
Sequences as illustrated by the large number of Sequences for 
all types of antibodies given in Kabat et al., 1987, hereby 
incorporated by reference. 
Messenger RNA isolated from the spleen or peripheral 
blood of an animal can be used as the template for the 
amplification of an antibody library. In certain 
circumstances, where it is desirable to display a homoge 
neous population of antibody fragments on the cell Surface, 
mRNA may be isolated from a population of monoclonal 
antibodies. Messenger RNA from either source can be 
prepared by Standard methods and used directly or for the 
preparation of a CDNA template. Generation of mRNA for 
cloning antibody purposes is readily accomplished by fol 
lowing the well-known procedures for preparation and char 
acterization of antibodies (see, e.g., Antibodies: A Labora 
tory Manual, 1988; incorporated herein by reference). 
Method of Producing Monoclonal Antibodies 
Generation of monoclonal antibodies (MAbs) follows 
generally the Same procedures as those for preparing poly 
clonal antibodies. Briefly, a polyclonal antibody is prepared 
by immunizing an animal with an immunogenic composi 
tion in accordance and collecting antisera from that immu 
nized animal. A wide range of animal Species can be used for 
the production of antisera. Typically the animal used for 
production of anti-antisera is a rabbit, a mouse, a rat, a 
hamster, a guinea pig or a goat. Because of the relatively 
large blood volume of rabbits, rabbits are usually preferred 
for production of polyclonal antibodies. 
Immunogenic compositions often vary in immunogenic 
ity. It is often necessary therefore to boost the host immune 
System, as may be achieved by coupling a peptide or 
polypeptide immunogen to a carrier. Exemplary and pre 
ferred carriers are keyhole limpet hemocyanin (KLH) and 
bovine serum albumin (BSA). Other albumins such as 
ovalbumin, mouse Serum albumin or rabbit Serum albumin 
can also be used as carriers. Recognized means for conju 
gating a polypeptide to a carrier protein are well known and 
include glutaraldehyde, m-male imidobenzoyl-N- 
hydroxySuccinimide ester, carbodiimides and bis-diazotized 
benzidine. 
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The immunogenicity of a particular immunogen compo 
Sition may be enhanced by the use of non-specific Stimula 
tors of the immune response, known as adjuvants. Exem 
plary and preferred adjuvants include complete Freund's 
adjuvant (a non-specific stimulator of the immune response 
containing killed Mycobacterium tuberculosis), incomplete 
Freund's adjuvants and aluminum hydroxide adjuvant. 
The amount of immunogen composition used in the 
production of polyclonal antibodies varies upon the nature 
of the immunogen as well as the animal used for immuni 
Zation. A variety of routes can be used to administer the 
immunogen (Subcutaneous, intramuscular, intradermal, 
intravenous and intraperitoneal). The production of poly 
clonal antibodies may be monitored by Sampling blood of 
the immunized animal at various points following immuni 
Zation. A Second, booster injection, may also be given. The 
process of boosting and titering is repeated until a Suitable 
titer is achieved. When a desired level of immunogenicity is 
obtained, the immunized animal can be bled and the Serum 
isolated, Stored and the Spleen harvested for the isolation of 
mRNA from the polyclonal response or the animal can be 
used to generate MAbs for the isolation of mRNA from a 
homogeneous antibody population. 
MAbs may be readily prepared through use of well 
known techniques, Such as those exemplified in U.S. Pat. 
No. 4,196,265, incorporated herein by reference. Typically, 
this technique involves immunizing a Suitable animal with a 
Selected immunogen composition, e.g. a Small molecule 
hapten conjugated to a carrier, a purified or partially purified 
protein, polypeptide or peptide. The immunizing composi 
tion is administered in a manner effective to Stimulate 
antibody producing cells. Rodents Such as mice and rats are 
frequently used animals; however, the use of rabbit, sheep 
frog cells is also possible. The use of rats may provide 
certain advantages (Goding, pp. 60–61, 1986), but mice are 
preferred, particularly the BALB/c mouse as this is most 
routinely used and generally gives a higher percentage of 
Stable fusions. 
Following immunization, Somatic cells with the potential 
for producing antibodies, specifically B lymphocytes (B 
cells), are selected for use in the MAb generating protocol. 
These cells may be obtained from biopsied Spleens, tonsils 
or lymph nodes, or from blood Samples. Spleen cells and 
blood cells are preferable, the former because they are a rich 
Source of antibody-producing cells that are in the dividing 
plasmablast Stage, and the latter because blood is easily 
accessible. Often, a panel of animals will have been immu 
nized and the Spleen of animal with the highest antibody titer 
will be removed and the spleen lymphocytes obtained by 
homogenizing the Spleen with a Syringe. Typically, a spleen 
from an immunized mouse contains approximately 5x107 to 
2x10 lymphocytes. 
The antibody-producing B lymphocytes from the immu 
nized animal are then fused with cells of an immortal 
myeloma cell, generally one of the same Species as the 
animal that was immunized. Myeloma cell lines Suited for 
use in hybridoma-producing fusion procedures preferably 
are non-antibody-producing, have high fusion efficiency, 
and enzyme deficiencies that render then incapable of grow 
ing in certain Selective media which Support the growth of 
only the desired fused cells (hybridomas). 
Any one of a number of myeloma cells may be used, as 
are known to those of skill in the art (Goding, pp. 65-66, 
1986; Campbell, 1984). For example, where the immunized 
animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, 
NS1/1Ag41, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11 
X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use 
R210. RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, 
GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all 
useful in connection with human cell fusions. 
One preferred murine myeloma cell is the NS-1 myeloma 











available from the NIGMS Human Genetic Mutant Cell 
Repository by requesting cell line repository number 
GM3573. Another mouse myeloma cell line that may be 
used is the 8-azaguanine-resistant mouse murine myeloma 
SP2/0 non-producer cell line. 
Methods for generating hybrids of antibody-producing 
Spleen or lymph node cells and myeloma cells usually 
comprise mixing Somatic cells with myeloma cells in a 2:1 
proportion, though the proportion may vary from about 20:1 
to about 1:1, respectively, in the presence of an agent or 
agents (chemical or electrical) that promote the fusion of cell 
membranes. Fusion methods using Sendai virus have been 
described by Kohler & Milstein (1975; 1976), and those 
using polyethylene glycol (PEG), such as 37% (v/v) PEG, 
by Gefter et al., 1977). The use of electrically induced fusion 
methods is also appropriate (Goding pp. 71-74, 1986). 
Fusion procedures usually produce viable hybrids at low 
frequencies, about 1x10 to 1x10. However, this does not 
pose a problem, as the viable, fused hybrids are differenti 
ated from the parental, unfused cells (particularly the 
unfused myeloma cells that would normally continue to 
divide indefinitely) by culturing in a selective medium. The 
Selective medium is generally one that contains an agent that 
blocks the de novo Synthesis of nucleotides in the tissue 
culture media. Exemplary and preferred agents are 
aminopterin, methotrexate, and azaserine. Aminopterin and 
methotrexate block de novo Synthesis of both purines and 
pyrimidines, whereas azaserine blocks only purine Synthe 
Sis. Where aminopterin or methotrexate is used, the media is 
Supplemented with hypoxanthine and thymidine as a Source 
of nucleotides (HAT medium). Where azaserine is used, the 
media is Supplemented with hypoxanthine. 
The preferred selection medium is HAT. Only cells 
capable of operating nucleotide Salvage pathways are able to 
survive in HAT medium. The myeloma cells are defective in 
key enzymes of the Salvage pathway, e.g., hypoxanthine 
phosphoribosyl transferase (HPRT), and they cannot sur 
vive. The B cells can operate this pathway, but they have a 
limited life Span in culture and generally die within about 
two weeks. Therefore, the only cells that can survive in the 
Selective media are those hybrids formed from myeloma and 
B cells. 
This culturing provides a population of hybridomas from 
which Specific hybridomas are Selected. Typically, Selection 
of hybridomas is performed by culturing the cells by Single 
clone dilution in microtiter plates, followed by testing the 
individual clonal Supernatants (after about two to three 
weeks) for the desired reactivity. Simple and rapid assays 
include radioimmunoassays, enzyme immunoassays, cyto 
toxicity assays, plaque assays, dot immunobinding assays, 
and the like. 
The selected hybridomas are serially diluted and cloned 
into individual antibody-producing cell lines from which 
clones can then be propagated indefinitely to provide MAbs. 
The cell lines may be exploited for MAb production in two 
basic ways. A Sample of the hybridoma can be injected 
(often into the peritoneal cavity) into a histocompatible 
animal of the type that was used to provide the Somatic and 
myeloma cells for the original fusion. The injected animal 
develops tumors Secreting the Specific monoclonal antibody 
produced by the fused cell hybrid. The body fluids of the 
animal, Such as Serum or ascites fluid, can then be tapped to 
provide MAbs in high concentration. The individual cell 
lines could also be cultured in vitro, where the MAbs are 
naturally secreted into the culture medium from which they 
can be readily obtained in high concentrations. MAbs pro 
duced by either means may be further purified, if desired, 
using filtration, centrifugation and various chromatographic 
methods such as HPLC or affinity chromatography. 
Following the isolation and characterization of the desired 
monoclonal antibody, the mRNA can be isolated using 
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techniques well known in the art and used as a template for 
amplification of the target Sequence. 
D. Amplification of a Target Gene Fragment using Enzy 
matic Polymerization 
A number of template dependent processes are available 
to amplify the target Sequences before and after mutagen 
esis. One of the best known amplification methods is the 
polymerase chain reaction (referred to as PCR) which is 
described in detail in U.S. Pat. Nos. 4,683,195, 4,683,202 
and 4,800,159, and in Innis et al. (1990), each of which is 
incorporated herein by reference in its entirety. Briefly, in 
PCR, two primer Sequences are prepared which are comple 
mentary to regions on opposite complementary Strands of 
the target Sequence. An excess of deoxynucleoside triphos 
phates are added to a reaction mixture along with a DNA 
polymerase, e.g., Taq polymerase. If the target Sequence is 
present in a Sample, the primers will bind to the target and 
the polymerase will cause the primers to be extended along 
the target Sequence by adding on nucleotides. By raising and 
lowering the temperature of the reaction mixture, the 
extended primers will dissociate from the target to form 
reaction products, exceSS primers will bind to the target and 
to the reaction products and the proceSS is repeated. Pref 
erably a reverse transcriptase PCR amplification procedure 
may be performed in order to quantify the amount of target 
amplified. Polymerase chain reaction methodologies are 
well known in the art. Using enzymatic amplification tech 
niques Such as PCR, desired control elements may be 
designed into the primer and thus, will be incorporated into 
the DNA product. 
Another method for amplification is the ligase chain 
reaction (“LCR”), disclosed in EPA No. 320 308, incorpo 
rated herein by reference in its entirety. In LCR, two 
complementary probe pairs are prepared, and in the presence 
of the target Sequence, each pair will bind to opposite 
complementary Strands of the target Such that they abut. In 
the presence of a ligase, the two probe pairs will link to form 
a Single unit. By temperature cycling, as in PCR, bound 
ligated units dissociate from the target and then Serve as 
“target Sequences” for ligation of exceSS probe pairs. U.S. 
Pat. No. 4,883,750 describes a method similar to LCR for 
binding probe pairs to a target Sequence. 
Qbeta Replicase, described in PCT Application No. PCT/ 
US87/00880, may also be used as an amplification method. 
In this method, a replicative sequence of RNA which has a 
region complementary to that of a target is added to a Sample 
in the presence of an RNA polymerase. The polymerase will 
copy the replicative Sequence which can then be detected. 
An isothermal amplification method, in which restriction 
endonucleases and ligases are used to achieve the amplifi 
cation of target molecules that contain nucleotide 5'-alpha 
thio-triphosphates in one Strand of a restriction site may 
also be useful in the amplification of nucleic acids (Walker 
et al., 1992). 
Strand Displacement Amplification (SDA) is another 
method of carrying out isothermal amplification of nucleic 
acids which involves multiple rounds of Strand displacement 
and Synthesis, i.e., nick translation. A similar method, called 
Repair Chain Reaction (RCR) involves annealing several 
probes throughout a region targeted for amplification, fol 
lowed by a repair reaction in which only two of the four 
bases are present. The other two bases can be added as 
biotinylated derivatives for easy detection. A similar 
approach is used in SDA. Target Specific Sequences can also 
be detected using a cyclic probe reaction (CPR). In CPR, a 
probe having a 3' and 5' Sequences of non-specific DNA and 











which is present in a Sample. Upon hybridization, the 
reaction is treated with RNaseH, and the products of the 
probe identified as distinctive products which are released 
after digestion. The original template is annealed to another 
cycling probe and the reaction is repeated. 
Other amplification methods are described in GB Appli 
cation No. 2 202 328, and in PCT Application No. PCT/ 
US89/01025, each of which is incorporated herein by ref 
erence in its entirety, may be used in accordance with the 
present invention. In the former application, "modified’ 
primers are used in a PCR like, template and enzyme 
dependent synthesis. The primers may be modified by 
labeling with a capture moiety (e.g., biotin) and/or a detector 
moiety (e.g., enzyme). In the latter application, an excess of 
labeled probes is added to a Sample. In the presence of the 
target Sequence, the probe binds and is cleaved catalytically. 
After cleavage, the target Sequence is released intact to be 
bound by excess probe. Cleavage of the labeled probe 
Signals the presence of the target Sequence. 
Other nucleic acid amplification procedures include 
transcription-based amplification Systems (TAS), including 
nucleic acid sequence based amplification (NASBA) and 
3SR (Kwoh et al., 1989). In NASBA, the nucleic acids can 
be prepared for amplification by Standard phenol/chloroform 
extraction, heat denaturation of a clinical Sample, treatment 
with lysis buffer and minispin columns for isolation of DNA 
and RNA or guanidinium chloride extraction of RNA. These 
amplification techniques involve annealing a primer which 
has target Specific Sequences. Following polymerization, 
DNA/RNA hybrids are digested with RNase H while double 
Stranded DNA molecules are heat denatured again. In either 
case the single stranded DNA is made fully double-stranded 
by addition of Second target specific primer, followed by 
polymerization. The double Stranded DNA molecules are 
then multiply transcribed by a polymerase such as T7 or 
SP6. In an isothermal cyclic reaction, the RNAS are reverse 
transcribed into double stranded DNA, and transcribed once 
against with a polymerase such as T7 or SP6. The resulting 
products, whether truncated or complete, indicate target 
Specific Sequences. 
Davey et al., EPA No. 329 822 (incorporated herein by 
reference in its entirety) disclose a nucleic acid amplification 
process involving cyclically Synthesizing Single-Stranded 
RNA (“ssRNA”), ssDNA, and double-stranded DNA 
(dsDNA), which may be used in accordance with the present 
invention. The ssRNA is a first template for a first primer 
oligonucleotide, which is elongated by reverse transcriptase 
(RNA-dependent DNA polymerase). The RNA is then 
removed from the resulting DNA:RNA duplex by the action 
of ribonuclease H (RNase H, an RNase specific for RNA in 
duplex with either DNA or RNA). The resultant ssDNA is a 
Second template for a Second primer, which also includes the 
Sequences of an RNA polymerase promoter (exemplified by 
T7 RNA polymerase) 5’ to its homology to the template. 
This primer is then extended by DNA polymerase 
(exemplified by the large “Kienow” fragment of E. coli 
DNA polymerase I), resulting as a double-stranded DNA 
(“dsDNA) molecule, having a sequence identical to that of 
the original RNA between the primers and having 
additionally, at one end, a promoter Sequence. This promoter 
Sequence can be used by the appropriate RNA polymerase to 
make many RNA copies of the DNA. These copies can then 
re-enter the cycle leading to very Swift amplification. With 
proper choice of enzymes, this amplification can be done 
isothermally without addition of enzymes at each cycle. 
Because of the cyclical nature of this process, the Starting 
sequence can be chosen to be in the form of either DNA or 
RNA. 
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Miller et al., PCT Application WO 89/06700 
(incorporated herein by reference in its entirety) disclose a 
nucleic acid Sequence amplification Scheme based on the 
hybridization of a promoter/primer Sequence to a target 
single-stranded DNA (“ssDNA) followed by transcription 
of many RNA copies of the Sequence. This Scheme is not 
cyclic, i.e., new templates are not produced from the result 
ant RNA transcripts. Other amplification methods include 
“race” and “one-sided PCR" (Frohman, 1990; O'Hara et al., 
1989). 
Methods based on ligation of two (or more) oligonucle 
otides in the presence of nucleic acid having the Sequence of 
the resulting “di-oligonucleotide, thereby amplifying the 
di-oligonucleotide, also may be used in the amplification 
step (Wu et al., 1989). 
Amplification products may be analyzed by agarose, 
agarose-acrylamide or polyacrylamide gel electrophoresis 
using standard methods (see, e.g., Maniatis et al. 1982). For 
example, one may use a 1% agarose gel Stained with 
ethidium bromide and visualized under UV light. 
Alternatively, the amplification products may be integrally 
labeled with radio- or fluorometrically-labeled nucleotides. 
Gels can then be exposed to X-ray film or visualized under 
the appropriate Stimulating spectra, respectively. 
E. Mutagenic Procedures 
Mutagenic procedures of the present invention may com 
prise any mutagenic approach that may be tailored to a 
particular site in a gene, i.e., Site-directed or Site-specific 
mutagenesis. Because the present invention relies on Satu 
ration mutagenesis, the present invention contemplates as 
preferred embodiments those mutagenic procedures that are 
rapid, efficient and cost effective. 
In one embodiment, the mutagenic procedure utilizes 
chemical Synthesis techniques. In So doing, it is possible to 
exactly place the Substitution at one or more particular 
locations within the gene, and also to specifically define the 
nature of the alterations. Chemical Synthesis methods for 
DNA are well known within the art. Solid phase techniques 
are preferred in this regard. 
One advantage to the Solid phase method of gene Synthe 
sis is the opportunity for mutagenesis using combinatorial 
Synthesis techniques. Combinatorial Synthesis techniques 
are defined as those techniques producing large collections 
or libraries of compounds Simultaneously, by Sequentially 
linking different building blockS. Libraries can be con 
Structed using compounds free in Solution, but preferably the 
compound is linked to a Solid Support Such as a bead, Solid 
particle or even displayed on the Surface of a microorgan 
S. 
Several methods exist for combinatorial synthesis 
(Holmes et al., 1995; Burbaum et al., 1995; Martin et al., 
1995; Freier et al., 1995; Pei et al., 1991; Bruce et al., 1995; 
Ohlmeyer et al., 1993), including split synthesis or parallel 
Synthesis. Split Synthesis may be used to produce Small 
amounts of a relatively large number of compounds, while 
parallel Synthesis will produce larger amounts of a relatively 
Small number of compounds. In general terms, using Split 
Synthesis, compounds are Synthesized on the Surface of a 
microparticle. At each Step, the particles are partitioned into 
Several groups for the addition of the next component. The 
different groups are then recombined and partitioned to form 
new groups. The process is repeated until the compound is 
completed. Each particle holds Several copies of the same 
compound allowing for facile Separation and purification. 
Split Synthesis can only be conducted using a Solid Support. 
An alternative technique known as parallel Synthesis may 
be conducted either in Solid phase or Solution. Using parallel 
Synthesis, different compounds are Synthesized in Separate 
receptacles, often using automation. Parallel Synthesis may 
be conducted in microtiter plate where different reagents can 











combinatorial library. Parallel synthesis is the preferred 
approach for use with enzymatic techniques. It is well 
understood that many modifications of this technique exist 
and can be adapted for use with the present invention. Using 
combinatorial methods, a large number of mutant gene 
templates may be Synthesized. 
Mutants genes also may be generated by Semisynthetic 
methods known in the art (Barbas et al., 1992). Using the 
conserved regions of an antibody fragment as a framework, 
variable regions can be inserted in random combinations one 
or more at a time to alter the Specificity of the antibody 
fragment and generate novel binding sites, especially in the 
generation of antibodies to antigens not conducive to immu 
nization Such as toxic or labile compounds. Along the same 
lines, a known antibody Sequence may be varied by intro 
ducing mutations randomly. This may be accomplished by 
methods well known in the art Such as the use of error-prone 
PCR. 
Using the appropriate oligonucleotide primers, PCR is 
used for the rapid synthesis of the DNA template containing 
one or more mutations in the binding protein gene. Site 
Specific mutagenesis is a technique useful in the preparation 
of individual peptides, or biologically functional equivalent 
proteins or peptides, through specific mutagenesis of the 
underlying DNA. The technique further provides a ready 
ability to prepare and test Sequence variants, incorporating 
one or more of the foregoing considerations, by introducing 
one or more nucleotide Sequence changes into the DNA. 
Site-specific mutagenesis allows the production of mutants 
through the use of Specific oligonucleotide Sequences which 
encode the DNA sequence of the desired mutation, as well 
as a Sufficient number of adjacent nucleotides, to provide a 
primer Sequence of Sufficient size and Sequence complexity 
to form a stable duplex on both sides of the deletion junction 
being traversed. Typically, a primer of about 17 to 25 
nucleotides in length is preferred, with about 5 to 10 residues 
on both sides of the junction of the Sequence being altered. 
The technique typically employs a bacteriophage vector 
that exists in both a single Stranded and double Stranded 
form. Typical vectors useful in Site-directed mutagenesis 
include vectorS Such as the M13 phage. These phage vectors 
are commercially available and their use is generally well 
known to those skilled in the art. Double stranded plasmids 
are also routinely employed in Site directed mutagenesis, 
which eliminates the Step of transferring the gene of interest 
from a phage to a plasmid. 
In general, Site-directed mutagenesis is performed by first 
obtaining a single-Stranded vector, or melting of two Strands 
of a double stranded vector which includes within its 
Sequence a DNA sequence encoding the desired protein. An 
oligonucleotide primer bearing the desired mutated 
Sequence is Synthetically prepared. This primer is then 
annealed with the Single-Stranded DNA preparation, taking 
into account the degree of mismatch when Selecting hybrid 
ization conditions, and Subjected to DNA polymerizing 
enzymes Such as E. coli polymerase I Klenow fragment, in 
order to complete the Synthesis of the mutation-bearing 
Strand. Thus, a heterodupleX is formed wherein one Strand 
encodes the original non-mutated Sequence and the Second 
strand bears the desired mutation. This heteroduplex vector 
is then used to transform appropriate cells, Such as E. coli 
cells, and clones are Selected that include recombinant 
vectors bearing the mutated Sequence arrangement. 
The preparation of Sequence variants of the Selected gene 
using site-directed mutagenesis is provided as a means of 
producing potentially useful Species and is not meant to be 
limiting, as there are other ways in which Sequence variants 
of genes may be obtained. For example, recombinant vectors 
encoding the desired gene may be treated with mutagenic 
agents, Such as hydroxylamine, to obtain Sequence variants. 
In certain applications, Substitution of amino acids by 
Site-directed mutagenesis, it is appreciated that lower Strin 
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gency conditions are required. Under these conditions, 
hybridization may occur even though the Sequences of probe 
and target Strand are not perfectly complementary, but are 
mismatched at one or more positions. Conditions may be 
rendered leSS Stringent by increasing Salt concentration and 
decreasing temperature. For example, a medium Stringency 
condition could be provided by about 0.1 to 0.25 M NaCl at 
temperatures of about 37 C. to about 55 C., while a low 
stringency condition could be provided by about 0.15 M to 
about 0.9 M salt, at temperatures ranging from about 20° C. 
to about 55 C. Thus, hybridization conditions can be readily 
manipulated, and thus will generally be a method of choice 
depending on the desired results. 
In other embodiments, hybridization may be achieved 
under conditions of, for example, 50 mM Tris-HCl (pH 8.3), 
75 mM KC1, 3 mM MgCl, 10 mM dithiothreitol, at tem 
peratures between approximately 20 C. to about 37 C. 
Other hybridization conditions utilized could include 
approximately 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 
AlM MgCl2, at temperatures ranging from approximately 40 
C. to about 72 C. Formamide and SDS also may be used to 
alter the hybridization conditions. 
In a particularly preferred embodiment, overlap PCR is 
employed as described in FIG. 3A and FIG. 3B and Example 
1. Briefly, a plasmid is used as a template for the first round 
of PCRTM, which was carried out under the preferred con 
ditions described in Example 1. The PCRTM products from 
the first round are purified and used, together with outside 
primers (Table 2), in the overlap extension PCRTM reaction. 
The end products contained the Site directed replacement of 
a given amino acid with all other possible amino acid 
residues. 
F. In Vitro Transcription/Translation 
The inventors have demonstrated that PCR mutagenesis 
coupled with Synthesis by in vitro transcription-translation 
and characterization of the protein product by quantitative 
ELISA can greatly simplify the engineering of polypeptides. 
In recent years there has been increased interest in the use 
of in vitro protein Synthesis to produce polypeptides for 
biochemical studies. Friguet et al (1993) used in vitro 
translation to generate C-terminal deletions in the B Subunit 
of tryptophan Synthase which were then employed to local 
ized the epitope Sequences of a panel of monoclonal anti 
bodies. Brand et al (1994) synthesized mutants of the 
proliferating cell nuclear antigen (CCNA) in vitro to probe 
for Sequences important for the oligomerization of the 
protein. 
However, So far in vitro protein Synthesis has not been 
employed for protein engineering Studies. The main reason 
is that the amount of polypeptide obtained from in Vitro 
transcription/translation is quite Small and therefore it is not 
adequate for rigorous biophysical analysis. However, the 
protein yield obtained by in vitro Synthesis is more than 
adequate for ligand binding and for determination of 
function, assuming that a Sensitive assay is available. This is 
particularly important for Saturation mutagenesis experi 
ments in which chosen residues are replaced with all of the 
20 amino acids. In Saturation mutagenesis it is important to 
identify the amino acid substitutions that abolish protein 
function. Furthermore, in vitro transcription-translation is 
ideally Suited for identifying amino acid replacements that 
enhance the protein function. 
By integrating PCR mutagenesis, in vitro transcription 
translation and functional characterization of the protein 
products in a microtiter well platform at the inventors have 
achieved over a ten-fold reduction in time over conventional 
Saturation mutagenesis. With automation, using a robotic 
Station, it is possible to achieve another ten-fold reduction 
for a total 100-fold reduction in the time and effort required 
for Saturation mutagenesis. This latter reduction will be 











Simultaneously using the robotic System. In this manner, the 
examination of thousands of amino acid Substitutions will 
finally become a reality and thus open new horizons in 
protein engineering and protein Structure-function Studies. 
The mutagenized DNA template for the polypeptide of 
interest can be cloned into a plasmid for in Vitro 
transcription/translation or in the preferred embodiment, the 
appropriate control elements are included within the PCR 
product for direct in vitro transcription/translation. In vitro 
transcription/translation of genes uses cell free extracts to 
provide the required enzymes, ribosomes and protein fac 
tors. The synthesis of proteins is directed by mRNA syn 
thesized from the desired DNA templates. The DNA tem 
plate must contain the appropriate control elements for the 
System used including a ribosome binding site and promoter 
Sequence. One of skill in the art would clearly recognize the 
appropriate required elements for each System. 
Prokaryotic in vitro techniques for protein production 
were the first to be used (Zubay et al., 1970). Subsequently 
eukaryotic Systems were developed using wheat germ 
(Roberts, 1973) and rabbit reticulocytes (Pelham, 1976). 
Several new developments have increased the efficiency of 
these techniques. Examples include, the development of 
nuclease deficient Strains of E. coli to improve the results 
using linear DNA templates (Yang, 1980) and treatment of 
reticulocyte lysates with micrococcal nuclease to lower any 
background expression from the System. 
The most recent systems developed for in vitro 
transcription/translation are based on transcription by phage 
RNA polymerases including SP6 and SP7 (Krieg, 1987, 
Studier, 1990). DNA placed under the control of T7 pro 
moter elements can be used as a template for in Vitro 
transcription by T7 RNA polymerase or for complete in vitro 
transcription/translation with the polymerase added to either 
a prokaryotic or eukaryotic protein synthesis System. While 
the methods of the present invention can be used with any 
in Vitro transcription/translation System, the T7 System is 
preferred for transcription and the use of a prokaryotic 
translation System is preferred as no capping of the RNA is 
required. 
Using in Vitro methods for translation, amino acid deriva 
tives may be incorporated into the protein by addition of the 
derivatized amino acid to the protein Synthesis System 
mixture. Varying the concentration of the derivatives, with 
respect to the normal amino acid, permits one to create a 
mixed population and measure relative effects. 
G. Characterization 
Mutant polypeptides generated by the present invention 
may be characterized using a variety of techniques. In 
general, protein products may be analyzed for the correct 
apparent molecular weight using SDS-PAGE. This provides 
an initial indication that the polypeptide was, in fact, Syn 
thesized. When compared to the natural molecule, it also 
indicates whether normal folding or processing is taking 
place with the mutant. In this regard, it may prove useful to 
label the polypeptide. Alternatively, the polypeptide may be 
identified by Staining of the gel. 
Beyond mere Synthesis, proteins may be characterized 
according to various properties and an extensive range of 
functions. Properties include isoelectric point, thermal 
Stability, Sedimentation rate and folding. One manner of 
examining folding is the ability to be recognized by a 
cognate binding partner. The prime example of this function 
is the antibody-antigen interaction. A wide variety of dif 
ferent immunoassay formats are available for this purpose 
and are well known in the art. Principally, changes in either 
affinity or Specificity can be determined when the protein is 
contacted with a specific ligand or panels of related ligands. 
Immunoassays can be generally divided into two types: 
heterogeneous assays requiring multiple Separation Steps, 
and homogeneous assays which are performed directly. 
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Heterogeneous immunoassays in general involve a ligand or 
antibody immobilized on a Solid matrix. A Sample contain 
ing a ligand is contacted with the immobilized antibody and 
the amount of complex formed on the matrix Support is 
determined from a label attached directly or indirectly to the 
immobilized complex. AS used in the context of the present 
invention, ligand is defined as a Species that interacts with a 
non-identical molecule to form a tightly bound, Stable com 
plex. For practical purposes, the binding affinity is usually 
greater than about 10M and is preferably in the range of 
10°-10'. M. The ligand may be any of several types of 
organic molecules, including alicyclic hydrocarbons, poly 
nuclear aromatics, halogenated compounds, benzenoids, 
polynuclear hydrocarbons, nitrogen heterocyclics, Sulfur 
heterocyclics, oxygen heterocyclics, and alkane, alkene 
alkyne hydrocarbons, etc. Biological molecules are of par 
ticular interest, including amino acids, peptides, proteins, 
lipids, Saccharides, nucleic acids and combinations thereof. 
Of course it will be understood that these are by way of 
example only and that contemplated immunoassay methods 
are applicable to detecting an extraordinarily wide range of 
compounds, So long as one can obtain an antibody that binds 
with the ligand of interest. 
Heterogeneous immunoassays may be performed as Sand 
wich assays in which a molecule of interest is reacted with 
an immobilized antibody that specifically binds that mol 
ecule with high affinity. In a Second Step, a conjugate formed 
from the same or different antibody to the antigen and a 
marker molecule is reacted with the antigen-antibody com 
plex on the immobilization matrix. After removal of exceSS 
free marker conjugate, the bound marker conjugate, which is 
proportional to the amount of ligand in the Sample, is 
measured. 
Detection of immunocomplex formation is well known in 
the art and may be achieved through the application of 
numerous approaches. These approaches are typically based 
upon the detection of a label or marker, Such as any of the 
radioactive, fluore Scent, chemilumine Scent, 
electrochemiluminescent, biological or enzymatic tags or 
labels known in the art. U.S. Patents concerning the use of 
Such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 
3,939,350; 3,996.345; 4,277,437; 4,275,149 and 4,366,241, 
each incorporated herein by reference. Of course, one may 
find additional advantages through the use of a Secondary 
binding ligand Such as a Second antibody or a biotin/avidin 
ligand binding arrangement, as is known in the art. 
Preferred methods for detection includes radioimmunoas 
say (RIA) or enzyme-linked immunosorbent assay (ELISA) 
with ELISA being most preferred due to generally increased 
Sensitivity. ELISAS are extensively used in biotechnology 
applications, particularly as immunoassays for a wide range 
of antigenic substances. The sensitivity of ELISA is based 
on the enzymatic amplification of the Signal 
Other preferred proteins contemplated for use in accor 
dance with the present invention are those which have a 
convenient assay for activity. Representative examples of 
target interactions include catalysis, enzyme-Substrate 
interactions, protein-nucleic acid interactions, receptor 
ligand interactions and protein-metal interactions. In these 
assays the mutant proteins can be compared with the wild 
type protein for changes in the ability to perform any of the 
foregoing functions. 
AS used herein, the term “contacting” is defined as 
bringing the reaction components into close enough proX 
imity to each other to allow the desired interaction to occur. 
Contacting may be accomplished by mixing the components 
in Solution, for example, or by heterogeneous interaction 
Such as by flow contact through a column or immobilizing 
matrix that binds to one of the components. 
For mutant proteins having a catalytic activity, the appro 
priate reaction may be monitored for a change in catalytic 












The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventors to function well within the 
practice of the invention, and thus can be considered to 
constitute preferred modes for of practice. However, those of 
skill in the art should, in light of the present disclosure, 
appreciate that many changes can be made in the Specific 
embodiments which are disclosed and still obtain a like or 





Taq polymerase was purchased from Promega (Madison, 
Wis.), dNTPs from Pharmacia (Uppsala, Sweden), and oli 
gonucleotide primers from Midland Certified Reagent 
(Midland, Tex.). Pyruvate kinase, tRNA, and nucleotide 
triphosphates were obtained from Boehringer Mannheim 
(Indianapolis, Ind.). Digoxin and digitoxin were purchased 
from Sigma (St. Louis, Mo.). Ouabain was purchased from 
Fluka (Ronkonkoma, N.Y.). 3-aminodeoxydigoxigenin 
hemisuccinimide was purchased from Molecular Probes 
(Eugene, Oreg.). Pful DNA polymerase was purchased from 
Stratagene (La Jolla, Calif.). The BIAcore 1000 and reagents 
including Sensor chip CM5, the amine coupling kit contain 
ing N-hydroxy succinmide (NHS), N-ethyl-N'-(3- 
diethylaminopropyl)carbodiimide (EDC), and ethanolamine 
hydrochloride were obtained from Pharmacia Biosensor AB 
(Uppsala, Sweden). 
PCRTM Mutagenesis 
Mutations in the ScFV(digoxin) antibody were generated 
by the overlapping PCRTM method (Ho et al., 1989; Horton 
and Pease, 1991; Higuchi et al., 1988) as depicted in FIG. 
3A. Briefly, the plasmid pET25b(scFv(Dig)) SEQ ID NO: 1 
(Burks and Iverson, 1995) was used as a template for PCRTM 
(SEQ ID NO:132 represents the amino acid sequence 
encoded by SEQ ID NO:1). For the first round PCRTM, a 2 
Kb-Nde I-Pvu I fragment from pET25b(scFv(Dig)) was 
used as the 3' template, whereas a 4 Kb, XhoI-Pvu I 
fragment was used as the 5' template. The restriction frag 
ments were isolated on an agarose gel to eliminate the 
possibility that any contaminating full-length, wild-type 
ScFV(Dig) construct was present. A list of the primers used 
for the first and second PCRTM steps are included in the 
Table 2. 
First round PCRTM was carried out in 50 mM KCl, 10 mM 
Tris-HCI pH 9.0 (25° C) 0.1% Triton X-100, 0.2 mM 
dNTPs, 2.5 units Taq polymerase (Promega), 0.6 uM each 
of the two primers and 0.05 lug template in 100 til total 
Volume. Amplification was carried out using the following 
Sequence: one cycle at 94 C. for 2 min; 29 cycles consisting 
of 94° C. for 1 min, 55° C. 2 min, and 72 C. for 3 min; one 
cycle of 94° C. for 1 min, 55° C. for 2 min and 72° C. for 
10 min. 
The PCRTM products from the first round were gel purified 
and used, together with outside primers (Table 2), in the 
overlap extension PCRTM reaction. For this round of PCRTM, 
the mix contained 50 mM KCl, 10 mM Tris0HCl pH 9.0 
(25° C) 0.1% Triton X-100, 0.2 mM dNTP's, 2.5 units Taq 
polymerase (Promega), 0.6 uM each of the two primers and 
0.05 ug each of both the 5'-template and the 3'-template in 
100 ul total volume. The amplification sequence for the 
overlap extension reaction was the same as for the first round 
reactions except that the annealing temperature for the first 
5 cycles was set between 48 C. and 55 C., depending on 
the Tm of overlapping sequence. The PCRTM products were 









Complete sequences for the sets of PCR" 




DOUBLE STOP 5'-AGCCAAACTACGCATTGACCATGAACGTTCG-3' 
(SEQ ID NO : 107) 
(SEQ ID NO : 108) 
(SEQ ID NO : 109) 
(SEQ ID NO : 110) 
CODON 
L96 SITE 
ATA 5'-AGCCAAACTACGCATGTTCCAGCAACGTTCG-3' (SEQ ID NO:111) 
ARG 5'-AGCCAAACTACGCATGTTCCACGTACGTTCG-3' (SEQ ID NO : 112) 
ASN 5'-AGCCAAACTACGCATGTTCCAAACACGTTCG-3' (SEQ ID NO : 113) 
ASP 5'-AGCCAAACTACGCATGTTCCAGACACGTTCG-3' (SEQ ID NO:114) 
CYS 5'-AGCCAAACTACGCATGTTCCATGCACGTTCG-3' (SEQ ID NO : 115) 
GLU 5'-AGCCAAACTACGCATGTTCCAGAAACGTTCG-3' (SEQ ID NO : 116) 
GLN 5'-AGCCAAACTACGCATGTTCCACAGACGTTCG-3' (SEQ ID NO:117) 
GLY 5'-AGCCAAACTACGCATGTTCCAGGCACGTTCG-3' (SEQ ID NO : 118) 
HIS 5'-AGCCAAACTACGCATGTTCCACACCGTTCG-3' (SEQ ID NO : 119) 
ILE 5'-AGCCAAACTACGCATGTTCCAATCACGTTCG-3' (SEQ ID NO: 120) 
LEU 5'-AGCCAAACTACGCATGTTCCACTGACGTTCG-3' (SEQ ID NO:121) 
LYS 5'-AGCCAAACTACGCATGTTCCAAAAACGTTCG-3' (SEQ ID NO: 122) 
MET 5'-AGCCAAACTACGCATGTTCCAATGACGTTCG-3' (SEQ ID NO: 123) 
PHE 5'-AGCCAAACTACGCATGTTCCATTCACGTTCG-3' (SEQ ID NO:124) 
SER 5'-AGCCAAACTACGCATGTTCCATCCACGTTCG-3' (SEQ ID NO: 125) 
THR 5'-AGCCAAACTACGCATGTTCCAACCACGTTCG-3' (SEQ ID NO: 126) 
TRP 5'-AGCCAAACTACGCATGTTCCATGGACGTTCG-3' (SEQ ID NO: 127) 
TYR 5'-AGCCAAACTACGCATGTTCCATACACGTTCG-3' (SEQ ID NO: 128) 
WAL 5'-AGCCAAACTACGCATGTTCCAGTTACGTTCG-3' (SEQ ID NO:129) 
PRMERS OF Tf 
PROMOTER AND TERMINATDR 
5'-PRIMER 5'-CGATGCGTCCGGCGTAGA-3' (SEQ ID NO : 130) 
3'-PRIMER 5'-GCTAGTTATTGCTCAGCGG-3' (SEQ ID NO:131) 
In Vitro Transcription/Translation 
In vitro protein Synthesis using an E. coli coupled 
transcription/translation System was carried out essentially 
as described (Kudlicki et al., 1994) and as outlined in FIG. 
3B. T7 RNA polymerase and S30 E. coli extract for coupled 
transcription/translation were prepared using Standard pro 
cedures (Kudlicki et al., 1994; Burks, 1996). 
The coupled transcription/translation reactions were car 
ried out in 30 ul total volume and the reaction mix contained 
the following: 55 mM Tris-acetate, pH 7.8, 2 mM DTT, 1.2 
mM ATP, 0.8 mM CTP, 0.8 mM GTP, 0.8 mM UTP, 2% 
polyethylene glycol (M.W. 8,000), 27 mM phosphoenol 
pyruvate, 0.4 mM cAMP, 35 lug/ml folinic acid, 30 mM 
ammonium acetate, 72 mM KOAc, 1.5 mM CaCOAc), 0.35 
mM of each amino acid, 0.5 mM EDTA, 0.3 mM glucose 




kinase, 20 ug t-RNA, 5ug rifampicin, 13.3 mM Mg(OAc) 
and 5ul of E. coli S30 fraction. Reactions were initiated by 
adding 0.5 lug of the DNA produced by overlap extension in 
7 ul. 
For radiolabelling of the protein synthesis products 0.083 
mM of S-Methionine (1175 Ci/mmole, New England 
Nuclear, Boston Mass.), was added to the reaction mixture. 
Reactions were incubated for 25 min at 37 C. with gentle 
shaking and were stopped by placing on ice. SDS-PAGE 
using in 15% polyacrylamide gels (Laemmli, 1970) and 
autoradiography was used to analyze the protein products. 
ELISA Screening 
Antibody capture ELISA was performed using Standard 
procedures (Harlow and Lane, 1988). The digoxin-BSA, 
digitoxin-BSA and Ouabain-BSA conjugates used in the 
ELISA analysis were prepared via Oxidization of the termi 
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nal Sugar residues with NaIO followed by covalent attach 
ment to BSA through reductive amination in the presence of 
NaBH (Smith et al., 1970). The digoxigenin-BSA conju 
gate was prepared from a direct reaction between BSA and 
3-aminodeoxydigoxigenin hemisuccinimide (Molecular 
Probes, Inc. Eugene, Oreg.) according to the manufacturers 
instructions. 
Microtiter plates were coated with 50 ul per well of 
hapten-conjugated BSA, at a concentration of 4 mg/ml and 
incubated at 4 C. for at least 18 hours. Prior to use, the 
plates were washed three times with PBS 140 mM NaCl, 
2.7 mM KC1, 10 mM NaHPO.7HO, 1.8 mMKHPO). 
Non-specific binding was blocked by coating with 5% w/v 
boiled powdered milk (Carnation) in PBS for 2 hours at 
room temperature followed by four washes with PBS alone. 
Aliquots from the transcription/translation reactions were 
diluted to a total of 50 ul with a solution of 1% w/v boiled 
powdered milk in PBS and incubated at room temperature 
overnight. After three washes with PBS, the plates were 
incubated for 1 hour at room temperature with 50 ul of a 0.28 
lug/ml of a murine monoclonal anti-HSV IgG Novagen 
(Madison, Wis.) in 1% w/v boiled powdered milk/PBS. 
Unbound antibody was removed by washing the plates three 
times with PBS and then incubated with the secondary 
antibody solution (50 ul per well of 0.2 mg/ml goat anti 
mouse IgG(H+L) conjugated to horseradish peroxidase 
(Pierce, Rockford, Ill.) diluted 1:500 in 1% w/v powdered 
milk/PBS). The plates were washed three times and were 
developed with the calorimetric horseradish peroxidase Sub 
strate 2,2'-azine-bis(3-ethylbenzothiazoline)-6-sulfonic acid 
diammonium salt (ABTS) (Pierce, Rockford, Ill.). The 
absorbance of each well of the ELISA plates was measured 
at 405 nm on a microplate autoreader when the ABTS 
reaction was Still in the linear range, a fact that was 
confirmed by taking Several time points per plate. 
For each cardiac glycoside being investigated (digoxin, 
digitoxin, digoxigenin, Ouabain), the absorbances for each 
mutant were linearly scaled to that of the wild-type scFv 
(Dig), which was assigned a value of 1.0, then plotted in the 
histograms (FIGS. 2A-2F). Wild-type scFv(Dig) was 
included on every ELISA plate to provide an internal 
calibration for results obtained on different plates. Truncated 
ScFV(Dig) polypeptides generated by Stop codon insertion 
exhibited no hapten binding and were thus used to establish 
the baseline in the ELISA assays. 
Expression and Purification of scFvs 
Single chain Fv mutants were produced and purified 
according to Burks (Burks and Iverson, 1995). The scFv 
genes from Second round overlap extension PCR were 
ligated into peT25b plasmid and transformed into E. Coli 
BL21 (DE3) strain. Inclusion bodies that consist of scEvs 
were isolated from cell lysates and dissolved in 8 M urea. 
Soluble scFVs were purified by a metal chelating column 
(IMAC) and refolded by dialyzing against Tris buffer (50 
mM Tris. HCl, pH 7.4,500 mM KC1, 10% glycerol). Protein 
concentrations were determined by ODs (X=44850) (Pace 
et al., 1995; Nieba et al., 1989). For the kinetics 
measurement, antibodies were further purified by a size 
exclusion gel filtration column Sepharose-75 (Pharmacia 
Biosensor AB, Sweden) to remove any dimeric or polymeric 
proteins. 
Surface Plasmon Resonance (SPR) Measurement of Single 
Chain Antibody Mutants 
The digoxin-BSA, digitoxin-BSA, digoxigenin-BSA and 
Ouabain-BSA conjugates were immobilized on the Surface of 
a sensor chip CM5 (approximately 400 RU) following the 











experiments were performed in buffer containing 150 mM 
NaCl, 10 mM HEPES, 3.4 mM EDTA, and 0.005% P20, pH 
7.4 at 25 C. with a flowrate of 60 ul/min (Myszka et al., 
1997; Zeder-Lutz et al., 1997; Oddie et al., 1997). ScFv 
proteins over the concentration range of 25 nM to 400 nM 
were added to the chip for the association rate measure 
ments. To prevent the rebinding of antibodies on the chip 
Surface, Soluble haptens (up to 1 mM) were added into 
elution buffer for the dissociation rate measurements (Schier 
et al., 1996). The antibody bound chip was regenerated by 
50% ethylene glycol, pH 10. The values of association and 
dissociation rate of antibodies were calculated using BIAe 
valuation Software from Pharmacia BioSensor. k was 
determined from a plot of (ln(dR/dt)/t versus concentration 
(Karlson et al., 1991). k was determined from a plot of 
ln(Ro/R) versus time. 
Amino Acid Index Analysis 
The amino acid index database, more than 402 different 
amino acid indices corresponding to the different properties 
of amino acid, have been retrieved through the internet 
(Tomi and Kanehisa, 1996). Normalized ELISA data was 




An example of an antibody system for which the in vitro 
Scanning Saturation mutagenesis System may be used is the 
high affinity anti-digoxin Single chain FV (ScFV(Dig)) 
(Huston et al., 1988; Burks and Iverson, 1995; Francisco et 
al., 1993) derived from the well-studied anti-digoxin 26-10 
murine monoclonal antibody (Mudgett-Hunter et al., 1982). 
Studies have shown that the 26-10 antibody binds to the 
cardiac glycosides digoxin, digitoxin and digoxigenin with 
high affinity (K, approximately 9x10" M') and with a 
42-fold lower affinity to ouabain (Schildbach et al., 1993). 
Digoxin and related cardiac glycosides (FIG. 1) consist of a 
5B, 148-steroid body, linked to an O.B-unsaturated lactone at 
C17 and an O-linked carbohydrate at position 3. The three 
dimensional structure of the 26-10 Fab complexed with 
digoxin (Jeffery et al., 1993) reveals that the 3'-tridigitoxose 
is exposed to the Solvent whereas the lactone ring is fully 
buried at the bottom edge of the binding site. Unlike other 
antibody-antigen complexes (Braden and Poljak, 1995), 
binding of digoxin to 26-10 Fab does not appear to cause 
detectable conformational changes of either the antibody or 
the hapten. Both affinity and specificity are derived entirely 
from Shape complementarity as no hydrogen bonds have 
been identified between digoxin and the antibody. 
Initially, six residues chosen for study, namely H:Tyr33, 
H: Asn35, H:TyrS0, H:Trp 100, L: Val94 and L: Pro 96 
(wherein the H and L designations refer to residues of the 
heavy chain and light chain, respectively) consist of three 
aromatic residues that define the largely hydrophobic walls 
of the binding pocket and thereby make extensive Van der 
Waals contact with hapten (heavy chain residues H:Tyr33, 
H:TyrS0 and H:Trp100), a residue that forms hydrogen 
bonds with contact residues and therefore is presumably of 
importance in maintaining the architecture of the binding 
pocket (H:ASn35) and, finally, two residues that define the 
bottom of the binding pocket (light chain residues L. Val94 
and L: Pro96). In an expanded study, two more aromatic 
residues (H:Tyr47 and H:Met100b), an additional hydrogen 
bond forming residue (H:Ser95) and an additional light 
chain residue that defines the bottom of the binding pocket 
(L:Thr91) also were characterized. 
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For each chosen residue, in Vitro Scanning Saturation 
mutagenesis was carried out. Briefly, at each Site, twenty 
one genes encoding all possible amino acid Substitutions as 
well as a double stop codon (control) were constructed by 
overlap extension PCR. The final products of the overlap 
extension PCR reaction contain a T7 promoter and ribosome 
binding site in front of the scrv gene. An HSV sequence is 
also present at the C-terminal end of the ScFv gene, So that 
the scFv protein can be detected by ELISA using an anti 
HSV monoclonal antibody. The PCR overlap extension 
products were used as templates for coupled in Vitro 
transcription-translation reactions to produce functional 
scFv proteins. An E. coli S30 ribosomal extract, as opposed 
to mammalian or plant cell extracts, was used for in Vitro 
translation. 
The protein products from the coupled in vitro 
transcription-translation Step were analyzed by ELISA. In 
the ELISA assays, 96-well microtiter plates were coated 
with the BSA conjugate of digoxin, digitoxin, digoxigenin, 


















































equal amounts from each of the in vitro synthesis reactions. 
In order to provide accurate calibration, the construct pre 
pared with the wild-type Sequence was used on each ELISA 
plate. It should be noted that the wild-type construct was 
produced by the overlapping PCR method alongside the 
mutants, thereby providing an accurate calibration for all 
stages of the procedure. The ELISA results for the different 
mutants binding to digoxin and the three analogs (760 
relative affinity values in all) were recorded. 
The single chain Fv form (scFV(Dig)) of the 26-10 
antibody was used Since the presence of only one polypep 
tide chain eliminates chain association difficulties that are 
possible with Fab antibodies. In the initial studies a total of 
114 mutant antibodies were produced all 19 Substitutions at 
each of the 6 chosen positions (Table 3). The mutants were 
analyzed for binding to digoxin, digitoxin, digoxigenin and 
Ouabain Via ELISA as described in Example 1, resulting in 
the generation of a comprehensive database of 456 relative 
affinity values. (Set 1=H:Tyr33; Set 2=H: Asn35; Set 
3=H:Tyr50; Set 4=Trp100; Set 5=L:Val94; Set 6=Pro96). 
TABLE 3 
Relative affinity values of mutants for digitoxin, digoxin, 
Ouabain and digitoxigenin as determined using ELISA 
Trp Tyr Phe His Ile Val Leu Pro Ala Gly Met 
1.54 1.OO O.85 0.45 O O.O8 O O O.O2 O.O8 O.71 
1.16 1.00 0.86 0.50 0.48 0.64 0.21 0.27 0.40 0.02 0.84 
1.33 1.OO O.95 0.26 O O O.O4 O.O5 OO6 O.2O O.30 
1.34 1.OO O.98 0.90 O.1O O.13 O.O4 O O.O4 O.O1 O.35 
O.O2 O.O2 O.O2 O.15 O15 O.13 O.22 O.2O O.24 O.19 O.39 
O.O2 O.O3 O.O2 O.O4 O.22 O.27 O.13 O.40 0.13 O.16 O.44 
O.O3 O.O3 OO1 O.12 O.O8 O13 O.O6 O.O3 O.O8 O.11 O.O4 
O O.O1 O O.O3 O.O3 O.O1 O.O3 O.O2 O.O3 O.O4 O.O3 
1.36 1.OO 101 O.19 OO1 O.04 0.12 O O.18 O.O1 O.31 
1.09 1.OO O.97 0.73 O.O2 O.O4 O.48 O O42 (0.13 O.75 
1.43 1.OO 113 O.23 O.17 O.OS 0.13 O.O1 O.27 O.15 O.O2 
1.2O 1.OO O.94 0.36 0.09 O O.O1 O O.O6 O.O5 O.15 
1.00 0.89 0.84 0.98 0.14 0.06 0.15 0.01 0.10 0.58 1.34 
1.OO 1.16 O.90 1.OO O.17 O.O8 O.2O O.08 O.52 O.89 1.08 
1.OO O.O3 O.31 O.26 O.08 O.O3 O.O6 O O O O.13 
1.OO O.S3 O.4O O.89 O.O5 O.O1 O.O6 O O O O.86 
3.88 2.01 4.32 1.36 1.10 1.00 0.46 1.50 0.87 1.23 1.83 
3.05 2.81. 4.80 1.61 0.84 1.00 1.25 1.40 1.26 1.22 2.16 
2.65 1.51 225 O.66 114 1.OO O.72 O.7O O.65 1.07 1.27 
1.95 1.96 3.65 1.03 1.16 1.00 0.86 0.66 0.88 0.67 2.00 
O O.58 0.87 O.O1 O.47 1.34 0.57 1.OO O.65 0.49 O.06 
O O.O1 O.O3 O 0.46 1.06 0.42 1.00 0.75 0.65 0.40 
O O.O6 O.O5 O O 1.00 0.56 1.00 0.64 0.05 0.01 
O O O O O 1.15 0.01 1.00 0.74 0.11 0.01 
Cys Thr Ser Glin Asn Glu Asp Lys Arg Stop 
O.36 0.04 O O O O O O.O3 O O 
O.62 O.19 O.14 O.2O O.27 O.22 O O.12 O.12 O 
O.10 O.11 O.O2 O O O.O3 O O O.O1 O 
O.12 O O O O O O O O.O3 O 
O.28 O.O3 O.72 O.66 1.OO O.OS O.24 O.21 O.12 O 
O.31 O.O5 O.71 O.72 1.OO O.O1 O.O5 O.O3 O.O3 O 
0.16 0.03 0.18 0.29 1.00 0.03 0.04 0.04 0.05 O 
O.O1 O.O1 O.31 O.42 1.OO O.O1 O.O2 O.O2 O.O2 O 
O.S3 O O.O4 O O O O O O.O1 O 
O.75 O.O6 O.13 O.30 O.80 O.O2 O O O O 
O.O9 O.O5 O.O5 O.15 O.O1 O.17 O.1O O.O3 O.04 O 
O.17 O O.O3 O.1O O.27 O.O7 O.O5 O O.O1 O 
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TABLE 3-continued 
Relative affinity values of mutants for digitoxin, digoxin, 
Ouabain and digitoxigenin as determined using ELISA 
4 Digitoxin 0.10 0.01 0.14 0.88 1.31 O O.O4 O.29 
4 Digoxin O.23 O.O2 O.37 1.18 1.35 O.O2 O.15 O.6O 
4 Ouabain O.O1 O O O.11 O.37 O O.O3 O 
4 Digitoxi- O O O O.43 O.98 0.05 O O 
genin 
5 Digitoxin 1.01 1.27 1.89 1.33 2.26 1.40 1.51 2.14 
5 Digoxin 1.12 1.15 1.36 1.20 1.40 1.48 1.95 1.88 
5 Ouabain O.95 1.3O O.94 1.28 1.61 1.27 O.69 1.90 
5 Digitoxi- O.99 1.07 1.07 1.25 18O O.98 O.29 2.13 
genin 
6 Digitoxin 0.85 0.99 0.75 O O.O3 O O O 
6 Digoxin O.69 O.90 O.85 O O.34 O O O 
6 Ouabain 0.51 1.18 0.42 O O O O O 
6 Digitoxi- O.69 O.99 0.64 O O O O O 
genin 
As described in Example 1, the inventors initial in vitro 
Scanning Saturation mutagenesis Studies were performed on 
Six residues that help define the interior of the anti-digoxin 
26-10 antibody binding pocket. For each residue, the PCR 
mutagenesis and in vitro transcription/translation Steps were 
carried out as described above in Example 1 in at least two 
independent runs to verify the reproducibility of the results. 
In addition, each ELISA, performed according to the pro 
cedure of Example 1, was run in duplicate. The reproduc 
ibility of the data was excellent, with absorbance values 
>20% of wild-type varying by no more than +5% between 
studies (performed by different investigators). ELISA values 
lower than 20% of wild-type exhibited a greater degree of 
variability, presumably because of the lower signal to noise 
ratio. A low or absent ELISA Signal was taken to mean that 
the off-rate was too fast for the scFv(Dig) mutants to remain 
bound to a significant extent during the incubations and 
Washing Steps, but does not necessarily imply complete loSS 
of binding. 
The ELISA results for the different mutants binding to 
digoxin and the three analogs (760 relative affinity values in 
all) are plotted as histograms in FIGS. 2A-2J. All absor 
bance values are normalized to the wild-type construct to 
allow for direct comparisons. It has been reported that the 
relative digoxin: digitoxin, digoxin: digoxigenin, and 
digoxin: Ouabain affinities are 2:1, 1:1, and 42:1, respec 
tively (Schildbach et al., 1993). Therefore, the relative 
ELISA values for the different cardiac glycosides in FIG. 
2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, FIG. 2F, FIG. 2G, 
FIG. 2H, FIG. 2I and FIG. 2J must be scaled accordingly 
before any direct comparisons are made. The excellent 
agreement between the values for relative affinities and 
Specificities for the different digoxin mutants in the literature 
(Short, et al., 1995; Schildbach et al., 1993; Schildbach et 
al., 1994; Near et al., 1993) underscores the validity of the 
inventors methodology for the rapid generation and char 
acterization of mutant antibodies. The data is useful in 
Several ways. From the histograms it is possible to detect the 
residues that were most tolerant to Substitution and, based on 
the types of Substitutions tolerated, better understand what 
Sorts of interactions are most important in antibody-antigen 
interaction. The mutagenisis assay was also able to uncover 
mutants with changed Specificity and mutants with binding 
interactions of over four times that of the wild-type. 
In particular, in this case, it was Striking that in initial 
studies 87 out of the 114 substitutions resulted in significant 
(>5% of wild-type) recognition and binding to one or more 


















large number of amino acid Substitutions is indicative of a 
high degree of plasticity in the antigen binding Site. The 
residue most tolerant of Substitution was L:Val94, where 
many amino acid Substitutions increased ELISAabsorbance 
values relative to the wild type. Increased absorbance values 
were especially apparent with large aromatic amino acid 
Substitutions Such as tryptophan and tyrosine, presumably 
due to increased Van der Waals contacts with the digoxin 
antigen. In contrast the three heavy chain aromatic residues 
that make Substantial Van der Waals contacts with bound 
digoxin in the wild type tolerated only more conservative 
changes that did not greatly increase digoxin binding or 
change Specificity; yet Surprisingly positively charged resi 
dues Such as lysine and arginine retained partial and full 
digoxin binding activity when substituted for H:Trp 100. The 
residue least tolerant to Substitution was H:ASn35, under 
Scoring the importance of hydrogen bonding in this residues 
interaction with digoxin. The most active replacements for 
ASn were Gln and Ser, residues also capable of hydrogen 
bonding interactions. Single residue changes did not change 
the order of antigen Specificity for digoxin relative to the 
larger Oubain, but were capable of changing the order of 
Specificity of the antibody for digoxigenin relative to 
digoxin. The difference between these two molecules lies in 
the Sugar moiety which does not play a Significant role in 
digoxin binding by the 26-10 antibody. 
EXAMPLE 3 
Further Elucidation of Specificity Determining 
Residues 
In additional Studies, values for the association and dis 
Sociation rate constants (k, and k, respectively) were 
measured using a BIAcore 1000 for the wild-type and 14 
selected mutant scFv antibodies. These included 3 light 
chain mutants and 11 heavy chain mutants of varying 
affinities (Table 4). The selected scEv antibodies were 
expressed and purified following the procedure described by 
Burks and Iverson (1995). In each case, care was taken to 
insure that the kinetic values measured on the BlAcore are 
free of artifacts due to rebinding or avidity effects arising 
from multimeric scFvs. In particular, gel filtration HPLC 
was used to confirm that each Scriv sample was 295% 
monomeric and a high flow rate (60 ul/min) as well as up to 
1 mM soluble hapten was used in the dissociation buffer to 
prevent rebinding during the dissociation measurements. For 
some of the low affinity mutants (K-10M) the values 
fork, could not be determined due to rapid dissociation and 
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practical limits on the maximum concentration of mutant 
scFv that could be used. The values for k of the mutants 
with higher overall affinity were obtained, all of which gave 
values near 10 M' s'. This value is very close to the 
38 
phobicity coefficient for an amino acid residue j is calculated 
as the sum of the Tanford-Jones hydrophobicity coefficients 
of all the residues contained within an 8 A Sphere centered 
on the a carbon of residue j. The average value of the 
maximum k for the binding of a monomeric antibody 5 hydrophobicity distribution, obtained for each amino acid 
(Schier et al., 1996; Foote and Eisen, 1995). On the other residue, is the mean hydrophobicity. 
hand, as is expected for a set of related antibodies, the There was a significant correlation between the ELISA 
mutations mostly affect the values of ker (Wells, 1996). data of H:33 and the hydrophobicity coefficients derived 
TABLE 4 
Association and Dissociation rate constants 
(kon and koff, respectively) for 
the wild-type and 14 selected mutant scEv antibodies. 
Digoxin Digitoxin 
kon koff Ka kon koff Ka 
WT 1.2 x 10 7.0 x 10 1.7 x 10 1.0 x 10° 1.3 x 10 7.7 x 10 
LC96F 1.0 x 10 2 5.0 x 10 1.18 x 10 0.014 8.4 x 107 
LC94Y 1.2 x 10° 5.2 x 10 2.3 x 10 1.15 x 10° 2.7 x 10; 4.3 x 10 
LC94F 1.2 x 10° 1.9 x 10 6.3 x 10 1.3 x 10° 1.3 x 10 1.0 x 10 
HC9ST 1.4 x 10° 5.4 x 10 2.6 x 107 1.0 x 10 O.11 9.0 x 10 
HC10OR 1.3 x 10° 5.0 x 10 2.6 x 10 9.3 x 10 8.2 x 10 1.1 x 10 
HC1OOK 9.4 x 10 8.0 x 102 1.2 x 107 O.09 O 
HC1OOH 1.0 x 10 2.0 x 10 5.0 x 10 9.7 x 103 O 
HCSOF 1.5 x 10° 5.8 x 10 2.6 x 10° 9.6 x 10 1.7 x 10 5.6 x 10 
HCSOH 9.7 x 10 4.0 x 105 2.4 x 10 1.0 x 10 O.162 6.2 x 10 
HCSON 1.1 x 10 9.0 x 10 1.2 x 10 1.0 x 10 O.256 3.9 x 10 
HCSOL 1.1 x 10° 4.5 x 102 2.4 x 107 O.208 O 
HCSOD 0.17 &1e7 8.0 x 10 2.1 3.8 x 10 
HCSOG 1.3 x 10 O.15 8.9 x 10 1.38 O 
HCSOA 1.2 x 10° O.10 1.2 x 107 9.6 x 102 O 
Ouabain Digitoxigenin 
kon koff Ka Kon kof Ka 
WT 1.0 x 10° 1.5 x 102 6.7 x 107 1.0 x 10 2.3 x 10° 4.3 x 10 
LC96F O.3 ND ND O.169 ND 
LC94Y 1.0 x 10° 1.7 x 102 6.0 x 107 1.1 x 10° 1.8 x 10. 6.1 x 107 
LC94F 1.0 x 10° 1.0 x 102 1.0 x 10 1.0 x 10 8.9 x 102 1.1 x 10 
HC9ST 1.0 x 10 O.12 6.7 x 10° 7.0 x 10 1.OO 7.0 x 10 
HC10OR 1.0 x 10 O.12 8.3 x 10° 7.0 x 10 1.7 x 10' 4.2 x 107 
HC1OOK O.60 ND 1.0 x 10° 1.48 6.7 x 10° 
HC1OOH 1.0 x 10° O.O9 1.1 x 107 1.0 x 10° 9.7 x 102 1.0 x 10 
HCSOF 1.0 x 10 0.013 7.9 x 107 1.0 x 10 2.2 x 10° 4.5 x 10 
HCSOH 1.0 x 10 1.6 6.2 x 10° 1.0 x 10° 3.5 x 10' 2.9 x 107 
HCSON 1.7 ND 1.1 x 10° 6.4 x 10 1.7 x 107 
HCSOL 1.4 ND 1.1 x 10° 1.13 1.0 x 107 
HCSOD O.14 ND 1.0 x 10 O.135 7.4 x 10 
HCSOG O.14 ND O.276 ND 
HCSOA 0.217 ND 1.6 x 10° O.163 9.9 x 10° 
The relative ELISA values produced in the in vitro 
Scanning Saturation mutagenesis Study were analyzed in the 50 
context of available amino acid indices. The goal of these 
analyses was to identify trends relating the observed ELISA 
Signals to the various properties of the amino acid side 
chains as quantified in the various indices. 
Hydrophobic effects often play a major role in antibody 
antigen interactions (Davies and Cohen, 1996), especially 
when hydrophobic haptens, Such as digoxin, are used. Over 
twenty different hydrophobic indices were evaluated with 
respect to the ELISA signals from the in Vitro Scanning 
Saturation mutagenesis experiments. In no case was an 
overwhelming correlation seen. As a representative 
example, Cid et al. (1992) derived a hydrophobicity scale 
from 60 protein Structures by considering the environment 
of each amino acid residue (Cid et al., 1992). They grouped 
the proteins into four Structural classes defined by Levitt and 
Chothia: C.C., Bf3, C+B, and C.B., where Class BB includes the 




from the Bf3 class of proteins (Cid et al., 1992). That is, 
replacing a less hydrophobic amino acid with a more hydro 
phobic amino acid generally results in a higher ELISA signal 
at residue H:33. The ELISA data at H:100b also correlates 
Somewhat to the hydrophobicity indices of the amino acid 
Substitutions), except for the bulky aromatic amino acids 
(Trp, Tyr, Phe, His) that are presumably too large. The 
correlation is much less compelling for residue H:50, while 
no pattern is identifiable for H:35, H:47, H:95, H:100, L:91, 
L:94 and L:96 even though these residues presumably make 
primarily hydrophobic contacts like H:33 and H: 100b. 
Despite there being no correlation between the ELISA 
Signals and hydrophobicity indices, one common trend for 
the five residues L:94, H:33, H:47, H:50 and H: 100 is that 
the Substitutions with aromatic amino acids retain the ELISA 
Signal, although in Some cases, (especially H: 100), Several 
non-aromatic residues of low hydrophobic indeX are also 
functional, albeit leSS active, Substitutes. 
Shape complementarity obviously influences the Speci 
ficity and affinity of antibody-hapten interactions. Proper fit 
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maximizes van der Waals interactions as well as the desol 
Vation that likely dominates the energetics of the hydropho 
bic binding of the 26-10 antibody-digoxin interaction 
(Jeffery et al., 1993). Therefore, an index derived from 
calculated van der Waals volumes (Fauchere et al., 1988) 
was used to analyze the effects of residue size. According to 
the crystal structure of wild-type 26-10, residues at the 
bottom of the binding pocket make close contact to prima 
rily the lactone and ring D portion of digoxin (Jeffery et al., 
1993). Consistent with this notion, the effect of substitutions 
at residues H:35, H:95, H:100b, L.91 and L:96 on binding 
activity varies according to the change of Van der Waals 
Volume of amino acid with the exception of amino acid 
whose Side chain may be too large to be accommodated 
within the binding pocket. In particular, the Substitutions at 
the above mentioned sites resulted in binding Similar to 
wild-type only when amino acids of Similar or Smaller size 
compared to wild-type were used. Residues L.91 and L:96 
are particularly noteworthy, as no other parameter examined 
was as important as Size at these positions. No correlation 
between van der Waals volume and binding activity could be 
observed for the other SDR residues. 
The 26-10 crystal Structure indicates hydrogen bonding 
involving H: Asn-35 and H:Ser-95 that could potentially play 
an important role in maintaining the Structural integrity of 
the binding site. Plots of the number of potential hydrogen 
bonding donors on a given side chain Versus the ELISA 
Signals for the different residues indicated that there is 
indeed a correlation of hydrogen bonding ability with 
ELISA signal at H:35, and a slightly weaker correlation at 
H:95. No other residues displayed a correlation with hydro 
gen bonding ability. 
The flexibility of the Side chains of the amino acids 
(Bhaskaran and Ponnuswamy, 1988) was also investigated. 
In general, most of the residues already identified as Show 
ing a preference for aromatic replacements, namely H:33, 
H:47, H:50 and L:94, also show a preference for more rigid 
Side chains. This, in fact, could well explain the aromatic, as 
opposed to simply hydrophobic preference, at these site. It 
is noteworthy that H:100, while generally preferring aro 
matic residues, also tolerates Significant flexibility. 
Discussion 
The in vitro Scanning Saturation mutagenesis Studies on 
the 26-10 antibody SDRs identified several single amino 
acid Substitutions that displayed remarkable changes 
inspecificity for digoxin and related cardiac glycosides. For 
example, the L: Pro-96 CXPhe mutant has a striking 
preference, greater than two orders of magnitude, in favor of 
binding digitoxin over digoxin, digoxigenin or Ouabain 
(Table 4). This effect is likely the result of an unfavorable 
steric interaction between the L: Pro-96{XPhe phenyl ring 
Side chain and the C12-OH group of digoxin, digoxigenin 
and ouabain that is absent in digitoxin. The H:Tyr-50KXASn, 
H:Trp-100KXLys and H:Trp-100KXHis mutants show a 
reciprocal Specificity, namely a strong preference for bind 
ing to digoxin and digoxigenin compared to digitoxin. 
Computer models have thus far not indicated a rationale for 
these changes in Specificity as especially the H:50 Side chain 
is far from the C12 position of bound digoxin in the 26-10 
Structure. 
Collectively, the data for all 190 mutants reveal several 
interesting trends. First, the 26-10 antibody binding pocket 
can be thought of as being relatively plastic, tolerating a 
large number of amino acid substitutions at the SDRs. Better 











retained binding affinities for digoxin of over 10-107 M'. 
Second, no single site SDR mutant was found to have a 
higher overall affinity for digoxin than the wild-type 26-10. 
This remarkable finding indicates that the immune System, 
presumably due to fine-tuning through Somatic 
hypermutation, has found an optimum Solution to the bind 
ing of digoxin when one considers only Single Substitutions. 
Thus, in the context of the immune response, the binding site 
of 26-10 could well represent the endpoint of affinity matu 
ration. 
Another way to look at the data for the 190 mutants is that 
simultaneous mutations in multiple SDRs would be neces 
Sary in order to increase further digoxin binding for 26-10. 
It is highly unlikely that multiple mutations in SDRs would 
occur simultaneously in B lymphocytes undergoing affinity 
maturation. However, it is possible to Select higher affinity 
antibodies with multiple mutations from combinatorial 
libraries in vitro. Using libraries displayed on the surface of 
E.coli and screened by FACS, a L:Val-94->Ile, L: Pro 
96->Ala double mutant with 3-fold higher affinity than 
wild-type was identified. As shown here, neither of these 
mutations alone showed higher affinity. Similarly, Short et 
al. (1995) used phage display to isolate a H:Thr-30->Pro, 
H: Asp-31->Ser, H:Met-34->Tyr triple mutant with about 
four-fold higher affinity to digoxin relative to the wild-type. 
In this latter case none of the mutated residues were SDRs. 
By combining the L:Val-94->Ile, L: Pro-96->Ala, H:Thr 
30->Pro, H: Asp-31->Ser, and H:Met-34->Tyr mutations an 
ScFv antibody was generated that has a Ka for digoxin of 
around 1.2x10' M', or 12-fold better than the wild-type 
scEv (GC, GG and BLI). 
There are three factors that can potentially influence the 
level of ELISA signal observed for any given mutant in the 
present investigations; 1) differences in the amount of trans 
lated protein produced in the coupled transcription/ 
translation reactions, 2) differences in the percentage of 
folded vs. unfolded protein for different mutants, and 3) 
relative affinities of the mutants produced. 
Repeated ELISA measurements have verified that there is 
little variation ELISA experiments, averaging only ti5%, 
indicating that the assay itself is not a significant Source of 
error. In addition, analysis of the in vitro translation products 
by Western blotting and by auroradiography demonstrated 
that the variability in the amount of scEv produced is less 
than +10% for different mutants. Thus, the observed differ 
ences in the ELISA values do not arise from the variations 
in protein synthesis levels. Rather, the ELISA values must 
reflect primarily differences in binding affinity or folding 
yield. It is not possible a priori to distinguish between these 
two possibilities. Nonetheless there are two lines of data 
indicating that in most cases the ELISA Signal reflects 
binding affinities: First, there is good agreement between the 
ELISA data and the relative affinities of several of the same 
26-10 mutants reported in the literature (Schildbach et al., 
1993; Short et al., 1995; Schildbach et al., 1994; Near et al., 
1993). Second, there is also good agreement between the 
affinities and Specificities measured for eleven of the four 
teen selected mutants by SPR and the ELISA data obtained 
from in vitro Scanning Saturation mutagenesis (Table 4). It is 
noteworthy that this correlation was observed even though 
the mutants analyzed were intentionally chosen to cover a 
range of affinities. 
For two L:94 mutants and one H: 100 mutant the ELISA 
Signal appeared to reflect differences in folding yield. For 
example, the in vitro Scanning Saturation mutagenesis 
ELISA data indicated that the L: Pro-94->Phe and L:Val 
94->Tyr mutants should have higher affinity than wild-type 
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26-10, while the SPR measurements indicate they do not. 
Similarly, the H:Trp-100->Arg mutant displayed an ELISA 
Signal that was equivalent to wild-type, even though mea 
Surements of the binding kinetics of the purified antibodies 
showed that this mutant has a somewhat lower affinity. 
In vitro expression levels of these mutants were found to 
be similar to wild-type by Western blot analysis, so by 
process of elimination, an enhanced folding ability may be 
responsible for the reproducibly increased ELISA signal. 
Consistent with this notion, the L: Pro-94->Phe, L: Pro 
94->Tyr and H:Trp-100->Arg mutants exhibited signifi 
cantly higher yields of active protein than the other ScF 
constructs using the same refolding protocol (Burks and 
Iverson, 1995). In general, the speed and large amount of 
data generated by in vitro Scanning Saturation mutagenesis 
must be weighed against the inability to determine without 
further analysis whether a particular mutation is affecting 
data generated by in vitro Scanning Saturation mutagenesis 
must be weighed against the inability to determine without 
further analysis whether a particular mutation is affecting 
folding or binding affinity. The issue of folding efficiency is 
interesting in its own right from a protein engineering 
perspective: mutants that do not fold with a Sufficiently high 
yield are of little interest for practical purposes whereas 
mutants exhibiting higher refolding yield than the wild-type 
antibody can be of considerable value for protein expres 
Sion. Finally, it must be pointed out that differences in 
refolding yields do not interfere in any way with the iden 
tification of mutants with interesting new binding Specifici 
ties. 
Because of the considerations discussed above no simple 
correlation between the ELISA signal and Kd values can be 
found. However, comparison of the data discussed herein 
indicates certain guidelines. For example, no ELISA reading 
is observed for affinities that are more than three orders of 
magnitude below wild-type, that is lower than 10 M'. 
However, a scaled ELISA reading of 0.4 corresponds to an 
affinity that is approximately two orders of magnitude below 
wild-type and a Scaled reading of 0.7–0.8 corresponds to an 
affinity that is one order of magnitude lower than wild-type. 
The ELISA data can also be used to evaluate the func 
tional roles played by the different SDRs. A positive corre 
lation between the ELISA data at a given residue and a 
quantified side chain attribute can be taken as evidence that 
the attribute in question is important for the functioning of 
the wild-type residue. Amino acid indices, intended to 
quantify the different Side chain parameters of 
hydrophobicity, flexibility, hydrogen bonding ability and 
Side chain Volume, were used for correctional analyses 
(Tomi and Kanehisa, 1996). 
Precise, quantitative correlations between ELISA data 
and any one amino acid indeX are not necessarily to be 
expected here, as the properties of amino acid Side chains are 
interrelated. In other words, it is reasonable to expect 
general trends indicating that more than one parameter, for 
example, both size and hydrogen bonding ability, are impor 
tant at an SDR as opposed to a correlation to any Single 
parameter. Consistent with this expectation, Strong correla 
tions with single parameters were observed with the ELISA 
data for only two residues at the bottom of the binding 
pocket, namely L:91 and L:96, which correlated with side 
chain Volume. However, Several Strong trends were identi 
fiable for each of the other residues when more than one 
parameter was considered, and these multi-parameter trends 
have allowed the construction of a working model for the 












Overall, side chain hydrophobicity showed a reasonably 
strong correlation with the ELISA data at H:33 and to a 
lesser extent H: 100b. The data for H: 100b was corrected for 
Size limitations by ignoring extremely large Side chains, 
which were inactive. The other SDI's showed no compelling 
relationship between ELISA signals and hydrophobicity. 
This observation transcends the exact hydrophobicity index 
used, as over twenty different hydrophobicity indices were 
investigated with results that were no better in terms of 
correlations than those presented herein using the index of 
Cid et al. (1992). The lack of general correlation for the other 
eight SDRs with hydrophobicity should not be used to argue 
against hydrophobic desolvation being the primary driving 
force for binding digoxin by 26-10. Rather, the lack of 
hydrophobic correlation was taken as evidence that other 
Side chain parameterS Such as rigidity, hydrogen bonding 
ability and size must also be important and Sometimes 
dominant. 
A general trend was identified for the five residues L:94, 
H:33, 1:47, H:50 and H: 100, which all strongly preferred 
aromatic residues as replacements, especially Tyr and Trp. 
These aromatic groups form a “collar” and one side (H:47) 
of the binding pocket cavity that may have a structural role. 
Flexible hydrophobic residues at these positions might tend 
to “collapse' in aqueous Solution, and perhaps the rigidity of 
the aromatic Side chains are required to maintain an open 
Structure, even in the absence of bound digoxin, analogous 
to the Wood framing used to shore up an underground mine 
shaft. One piece of evidence to Support this notion is that 
asSociation rate constants of 26-10 mutants are all very close 
to 1x10° (M's) based on SPR data, indicating that the 
mutant binding pockets are “open’ in the unbound State. In 
addition, the crystal structure of other antibodies complexed 
to hydrophobic haptens show a similar “hydrophobic collar' 
in their binding pocket (Wedemeyer et al., 1997). Thus, it 
appears that hydrophobicity coupled to the rigidity of the 
aromatic residues are important at key Sites within 26-10 and 
perhaps other antibodies that have hydrophobic binding 
Sites. Such a central role for these aromatic residues based 
on both rigidity and hydrophobicity likely explains the 
predominance of Solvent exposed tyrosine and tryptophan in 
antibody binding pockets (Padlan, 1996). 
Size appears to be a key parameter for the residues at the 
bottom of the binding pocket, namely H:100b, L.91 and 
L:96. In each case, ELISA signals increased with increasing 
residue size to a point, then fell off rapidly for the largest Side 
chains. The binding pocket Structure is likely robust enough 
at the bottom to prevent hydrophobic collapse So that 
considerable flexibility can be accommodated, thereby 
explaining why no correlation to rigidity was observed. 
Interestingly, most of the “specificity' mutants occurred at 
these bottom positions, ex. L:96. Perhaps it will turn out to 
be a general feature of antibodies that fewer Structural 
rigidity constraints at the bottom of the pocket permit more 
fine tuning of the fit at these positions. Interestingly, as 
previously mentioned, mutants at H: 100b showed a corre 
lation with hydrophobicity, but L:91 and L:96 displayed no 
recognizable hydrophobicity pattern. Thus, for these latter 
two residues, Size appears to be the clearly predominant 
parameter. 
Hydrogen bonding along with size appear to be the key 
parameters for residues H:35 and H:95. Presumably hydro 
gen bonding is required to maintain the Structural integrity 
of the binding pocket. Interestingly, a largely hydrogen 
bonding Structural role was previously predicted for both 
asparagine and Serine based on the observation that they are 
overrepresented in antibody binding pockets, yet have a 
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relatively Small contact Surface area with bound antigen 
(Padlan, 1996). 
In vitro Scanning Saturation mutagenesis could prove 
particularly valuable for protein engineering Studies, even 
with enzymes when coupled to a catalytic assay, as a rapid 
way of identifying mutants with interesting properties that 
can then be produced in large quantity and Subjected to more 
detailed Structural and functional characterization. In 
addition, in vitro Scanning Saturation mutagenesis represents 
a Systematic new tool for exploring in vitro antibody affinity 
evolution, analogous to Somatic hypermutation in Vivo. 
Interesting Single mutants can be used as a starting point for 
Subsequent rounds of in vitro Saturation mutagenesis at other 
Sites, So that multiple mutations with Synergistic effects on 
binding may be identified. This Same Sequential mutation 
approach should be useful with other types of proteins, So 
that attributes Such as expression level, folding ability, 
catalytic rate or Substrate Specificity could be modulated in 
a Systematic way. 
All of the composition and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the compositions and methods and in the Steps or 
in the Sequence of Steps of the method described herein 
without departing from the concept, Spirit and Scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be Substituted for the agents described herein 
while the same or similar results would be achieved. All 
Such similar Substitutes and modifications apparent to those 
skilled in the art are deemed to be within the Spirit, Scope and 
concept of the invention as defined by the appended claims. 
H. References 
The following references, to the extent that they provide 
exemplary procedural or other details Supplementary to 
those Set forth herein, are specifically incorporated herein by 
reference: 
Barbas et al., Proc. Natl. Acad. Sci. USA, 88: 7978–7982, 
1991. 
Barbas et al., Proc. Natl. Acad. Sci. USA, 89:4457-4461, 
1992. 
Bhaskaran and Ponnuswamy, Int. J. Peptide Protein Res. 32, 
241-255, 1988. 
Blackburn et al., Clin. Chem., 37:1534–1539, 1991. 
Braden et al., FASEB Journal, 9:9-16, 1995. 
Braisted and Wells, Proc. Nat 'l Acad. Sci. 
93:5688-5692, 1996. 
Brand et al., J Immunol, 153(7):3070–8, 1994. 
Brand et al., J immunol, 152(8):4120-4128, 1994. 
Breyer and Sauer, J Biol Chem, 264(22): 13355–60, 1989. 
Brown et al., J. Immunology, 156:3285-3291, 1996. 
Bruce et al., Rapid Commun Mass Spectrom, 9(8):644-50, 
1995. 
Brummell et al., Biochemistry, 32:1180–1187, 1993. 
Brutlag et al., Comput Appl BioSci, 6(3):237-45, 1990. 
Burbaum et al., Proteins, 7(2):99-111, 1990. 
Burks and Iverson, Biotechnol. Prog., 11:112-114, 1995. 
Burks et al., Proc. Natl. Acad. Sci. USA, 94:412–417, 1997. 
Burton and Barbas, Adv: Immunol., 3rd, 57:191-280, 1994. 
Campbell, in: Monoclonal Antibody Technology, Laboratory 
Techniques in Biochemistry and Molecular Biology, Vol. 
13, Burden & Von Knippenberg, Amsterdam, Elseview, 
pp. 75–83, 1984. 













Chou and Fasman, Biochemistry, 13(2):211-222, 1974b. 
Chou and Fasman, Ann. Re: Biochem., 47:251–276, 1978b. 
Chou and Fasman, Biophys.J., 26:367-384. 1979. 
Chou and Fasman, Biochemistry, 13(2):222-245, 1974a. 
Chou and Fasman, Adv: Enzymol. Relat. Areas Mol. Biol., 
47:45-148, 1978a. 
Cid et al. Protein Engineering, 5:373-375. 1992. 
Clackson and Wells, Science, 267(5196):383–6, 1995. 
Cunningham et al., Science, 243(4896): 1330–1336, 1989. 
Davey et al., EPA No. 329822 
Davidson and Sauer, Proc Natl Acad Sci., 91(6):2146-50, 
1994. 
Davidson et al., Nat Struct Biol, 2 (10) p856–64, 1995. 
Davies and Cohen, Proc. Nat. Acad. Sci., USA 93, 
7-12.1996. 
EPA No. 32O3O8 
Fauchere et al., Int. J. Peptide Protein Res., 32:269-278 
1988. 
Fetrow and Bryant, Biotechnology, 11(4):479-84, 1993. 
Foote and Eisen, Proc. Natl. Acad Sci. USA, Vol. 92, 
1254-1256. 1995. 
Francisco et al., Proc. Nat’l Acad. Sci. 
90:10444–10448, 1993. 
Freier et al., J Med Chem, 38(2):344–52, 1995. 
Friguet et al., J Immunol Methods., 158(2):243-249, 1993. 
Frohman, In: PCR Protocols. A Guide to Methods and 
Applications, Academic Press, N.Y., 1990. 
GBApplication No. 2 202 328 
Gefter et al., Somatic Cell Genet., 3:231-236, 1977. 
Goding, in: Monoclonal Antibodies. Principles and 
Practice, 2nd Ed., Orlando, Fla., Academic Press pp. 
60–61, 65-66, 71–74, 1986. 
Harlow and Lane, Antibodies. A Laboratory Manual, Cold 
Spring Harbor Lab. Press, New York, 1988. 
Harrison et al., Methods Enzymol, 267: 109-115, 1996. 
Higuchi et al., Nucleic Acid Res., 16:7351–7367, 1988. 
Hilton et al., J. Biol. Chem., 271:4699–4708, 1996. 
Ho et al., Gene, 77:51-59, 1989. 
Holmes et al., Biopolymers, 37(3):199-211, 1995. 
Horton and Pease, (M. J. McPherson, ed), 217-247, Oxford 
University Press, New York, N.Y., 1991. 
Huston et al., Methods in Enzymology, “Molecular Design 
and Modeling: Concepts and Applications,' Abelson & 
Simon, Academic PreSS, Inc., San Diego, pp. 46-99, 
1991. 
Huston et al., Proc. Nat'l Acad. Sci. USA, 85:5870-5883, 
1988. 
Innis et al., PCR Protocols, Academic Press, Inc., San Diego 
Calif., 1990. 
Ito et al., J. Biol. Chem., 268:16639–16647, 1993. 
Iverson et al., Cold Spring Harbor Symposia on Quantitative 
Biology, 54:273-281, 1989. 
Jackson et al., J. Immunol., 154:3310-3319, 1995. 
Jameson and Wolf, Comput. Appl. BioSci., 4(1): 181-186, 
1988. 
Jeffery et al., Proc. Nat'l Acad. Sci. USA, 90:10310–10314, 
1993. 
Kabat et al., In: Sequences of Proteins of Immunological 
Interest, U.S. Dept. of Health and Human Services, U.S. 
Government Printing Office, 1987. 
Karlson et al., J. Immunol. Methods, 145, 229-240. 1991. 
Kohler and Milstein, Eur: J. Immunol. 6:511–519, 1976. 
Kohler and Milstein, Nature, 256:495-497, 1975. 
Krieg and Melton, Methods Enzymol, 155 p397–415, 1987. 
Kudlicki et al., J. Biol. Chem..., 269:16549-16553, 1994. 
Kwoh et al., Proc. Nat. Acad. Sci. USA, 86:1173–1177, 
1989. 
USA, 
US 6, 180,341 B1 
45 
Kyte and Doolittle, J. Mol. Biol. 157, 105-132,1982. 
Laemmli, U. K., Nature, 227:680–685, 1970. 
Levitt and Chothia, Nature, 261 (5561):552-558, 1976. 
Lilleholand Malik, Adv Appl Microbiol., 38:149-209, 1993. 
46 
Schildbach et al., J. of Biol. Chem., 268:21739-21747, 
1993b. 
Schildbach et al., Protein Science, 2:206–214, 1993a 
Schildbach et al., Protein Science, 3: 737-749, 1994. 
Makrides, S. C., Microbiol. Rev., 60(3):512-538, 1996. 5 Short et al., J. Biol. Chem., 270:28541-28550, 1995. 
Maniatis et al., Molecular Cloning. A Laboratory Manual, Smith et al., Biochemistry, 9:331-337, 1970. 
Cold Springs Harbor Laboratories, Cold Springs Harbor, Studier et al., Methods Enzymol, 185:60-89, 1990. 
N.Y., 1982. Tomii and Kanehisa, Protein Engineering, 9:27-36, 1996. 
Maniatis et al., Molecular Cloning. A Laboratory Manual, U.S. Pat. No. 3,817,837 
Cold Springs Harbor Laboratories, Cold Springs Harbor, 10 U.S. Pat. No. 3,850,752 
N.Y., 1989. U.S. Pat. No. 3,939,350 
Martin et al., J Med Chem., 38(9): 1431–1436, 1995. U.S. Pat. No. 3,996,345 
Matthews, Adv. Prot. Chem., 46:249-278, 1995. U.S. Pat. No. 4,196,265 
Miller et al., PCT Application WO 89/06700 U.S. Pat. No. 4,275,149 
Morrison, S. L., Annu Rey Immunol, 10:239–65, 1992. 15 U.S. Pat. No. 4,277,437 
Mudgett-Hunter et al., J. Immnol., 129:1165-1172, 1982. U.S. Pat. No. 4,366,241 
Myszka et al., Biophysical Chemistry, 64:127-137, 1997. U.S. Pat. No. 4,554,101 
Near et al., Mol. Immun., 30:369-377, 1993. U.S. Pat. No. 4,683,195 
Nicholls, et al., J Biol Chem., 268(7):5302-5308, 1993. U.S. Pat. No. 4,683,202 
Nieba et al., Anal. Biochem..., 234:155–165, 1996. 20 U.S. Pat. No. 4,800,159 
O'Hara, et al., Proc. Nat'l Acad. Sci. USA, 86:5673–5677, U.S. Pat. No. 4,883,750 
1989. U.S. Pat. No. 5,221,605 
Oddie et al., Anal. Biochem. 244, 301–311, 1997. U.S. Pat. No. 5,238,808 
Ohlmeyer et al., Proc Natl AcadSci, 90 (23), 1993. Walker et al., Proc. Nat'l Acad. Sci. USA, 89:392–396, 1992. 
Pace et al., Protein Science, 4:24 11-2423, 1995. 25 Warren et al., Biochemistry, 35:8855-8862, 1996. 
Padlan, Advances in Protein Chemistry., 49:57-133, 1996. Wedemeyer et al., Science, 276, 1665–1669 1997. 
Parker, C. W., In Handbook of Experimental Immunology, Weinberger et al., Science, 228(4700):740–2, 1985. 
3rded, (Weir DM ed), Blackwell Scientific, Oxford, 1978. Wells and de Vos, Annu Rev Biophy's Biomol Struct, 
PCT Application No. PCT/US87/00880 22:329–51, 1993. 
PCT Application No. PCT/US89/01025, Science, 253: 30 Wells, J. A., Proc. Nat'l Acad. Sci. USA, 93:1–6, 1996. 
(5026): 1408–11, 1991. Wolf et al., Comput. Appl. BioSci., 4(1):187-191, 1988. 
Pelham et al., Eur J Biochem. 67(1): 247-256, 1976. Wong et al., J. Immunol., 154:3351–3358, 1995. 
Reidhaar-Olson and Sauer RT, Science, 241(4861):53-7, Wu et al., Genomics, 4:560-569, 1989. 
1988. Yang et al., Proc Natl Acad Sci., 77(12):7029–7033, 1980. 
Reidhaar-Olson and Sauer, Proteins, 7(4):306–16, 1990. 35 Yelton et al., J. Immunol., 155:1994–2004, 1995. 
Roberts et al., Br J Haematol. 25(2):203-206, 1973. Zeder-Lutz et al., Anal. Biochem., 246:123-132. 1997. 
Schier et al., J. Mol. Biol. 263, 551–567, 1996. Zubay et al., Proc Natl AcadSci, 66(1):104–10, 1970. 
SEQUENCE LISTING 
(1) GENERAL INFORMATION: 
(iii) NUMBER OF SEQUENCES: 132 
(2) INFORMATION FOR SEQ ID NO : 1 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 1010 base pairs 
(B) TYPE : nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 1 : 
CGATGCGTCC GGCGTAGAGG ATCGAGATCT CGATCCCGCG AAATTAATAC GACT CACTAT 60 
AGGGGAATTG. TGAGCGGATA ACAATTCCCC. TCTAGAAATA ATTTTGTTTA ACTTTAAGAA 120 
GGAGATATAC ATATGGAAGT, TCAACTGCAA CAGTCTGGTC. CTGAATTGGT TAAACCTGGC 18O 
GCCTCTGTGC GCATGTCCTG CAAATCCTC.A. GGGTACATTT TCACCGACTT CTACATGAAT 240 
TGGGTTCGCC AGTCTCATGG TAAGTCTCTA GACTACATCG GGTACATTTC CCCATATTCT 3OO 
GGGGTTACCG GCTACAACCA GAAGTTTAAA GGTAAGGCCA CCCTTACTGT, CGACAAATCT 360 
TCCTCAACTG CTTACATGGA GCTGCGTTCT TTGACCTCTG AGGACTCCGC GGTATACTAT 420 
47 
TGCGCCGGCT CCTCTGGTAA CAAATGGGCC ATGGATTATT 
ACTGTGAGCT. CTGGTGGCGG, TGGCTCGGGC GGTGGTGGGT 
ATAGTACTGA CCCAGTCTCC AGCTTCTTTG GCTGTGTCTC 
TCCTGCCGAT CCAGCCAAAG TCTCGTACAT. TCTAATGGTA 
CAACAGAAAC CAGGACAGCC ACCCAAGCTT CTCATCTATA 
GGAGTCCCTG CCAGGTTCAG TGGCAGTGGG TCTGAGTCAG 
CCTGTGGAGG AAGATGATGC TGCAATATAT TACTGTAGCC 
ACGTTCGGCT, CGGGGACCAA GCTCGAGATC AAACGGGCTA 
GAAGACCCCG AGGATGTCGA, GCACCACCAC CACCACCACT 
GCCCGAAAGG AAGCTGAGTT GGCTGCTGCC ACCGCTGAGC 
(2) INFORMATION FOR SEQ ID NO: 2: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:2: 
CGGTGAAAAT GTACCCTG 
(2) INFORMATION FOR SEQ ID NO:3: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:3: 
CAGGGTACAT TTTCACCGAC TTCTACATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 4: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 4: 
CAGGGTACAT TTTCACCGAC TTCGCAATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 5: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:5: 
CAGGGTACAT TTTCACCGAC TTCCGTATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 6: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
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(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 6: 
CAGGGTACAT TTTCACCGAC TTCAACATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 7 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 7 : 
CAGGGTACAT TTTCACCGAC TTCGACATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 8: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:8: 
CAGGGTACAT TTTCACCGAC TTCTGCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 9: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 9: 
CAGGGTACAT TTTCACCGAC TTCGAAATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 10 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:10: 
CAGGGTACAT TTTCACCGAC TTCCAGATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 11: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 11: 
CAGGGTACAT TTTCACCGAC TTCGGCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 12: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
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(xi). SEQUENCE DESCRIPTION: SEQ ID NO:12: 
CAGGGTACAT TTTCACCGAC TTCCACATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 13: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 13: 
CAGGGTACAT TTTCACCGAC TTCATCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 14 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:14: 
CAGGGTACAT TTTCACCGAC TTCCTGATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO:15: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:15: 
CAGGGTACAT TTTCACCGAC TTCAAAATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 16: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:16: 
CAGGGTACAT TTTCACCGAC TTCATGATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 17: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:17: 
CAGGGTACAT TTTCACCGAC TTCTTCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 18 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
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(xi). SEQUENCE DESCRIPTION: SEQ ID NO:18: 
CAGGGTACAT TTTCACCGAC TTCCCGATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 19: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:19: 
CAGGGTACAT TTTCACCGAC TTCTCCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 2O: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:20 : 
CAGGGTACAT TTTCACCGAC TTCACCATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 21: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 21: 
CAGGGTACAT TTTCACCGAC TTCTGGATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 22: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:22: 
CAGGGTACAT TTTCACCGAC TTCGTTATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 23: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 36 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:23: 
CAGGGTACAT TTTCACCTGA TTCTGAATGA ATTGGG 
(2) INFORMATION FOR SEQ ID NO: 24 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 20 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
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GTAGAAGTCG GTGAAAATGT 
(2) INFORMATION FOR SEQ ID NO:25: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:25: 
ACATTTTCAC CGACTTCTAC ATGGCATGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:26: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:26: 
ACATTTTCAC CGACTTCTAC ATGCGTTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO: 27: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:27: 
ACATTTTCAC CGACTTCTAC ATGAACTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:28: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:28: 
ACATTTTCAC CGACTTCTAC ATGGACTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:29: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:29: 
ACATTTTCAC CGACTTCTAC ATGTGCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:30: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
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ACATTTTCAC CGACTTCTAC ATGGAATGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:31: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:31: 
ACATTTTCAC CGACTTCTAC ATGCAGTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:32: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:32: 
ACATTTTCAC CGACTTCTAC ATGGGCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:33: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:33: 
ACATTTTCAC CGACTTCTAC ATGCACTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:34: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:34: 
ACATTTTCAC CGACTTCTAC ATGATCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:35: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:35: 
ACATTTTCAC CGACTTCTAC ATGCTGTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:36: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:36: 
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(2) INFORMATION FOR SEQ ID NO:37: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:37: 
ACATTTTCAC CGACTTCTAC ATGATGTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:38: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:38: 
ACATTTTCAC CGACTTCTAC ATGTTCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:39: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:39: 
ACATTTTCAC CGACTTCTAC ATGCCGTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO: 40: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:40: 
ACATTTTCAC CGACTTCTAC ATGTCCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:41: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:41: 
ACATTTTCAC CGACTTCTAC ATGACCTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO: 42: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 42: 
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-continued 
(2) INFORMATION FOR SEQ ID NO:43: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 43: 
ACATTTTCAC CGACTTCTAC ATGTACTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:44: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:44: 
ACATTTTCAC CGACTTCTAC ATGGTTTGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO: 45: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 45: 
ACATTTTCAC CGACTTCTAC TGATGATGGG TTCGC 
(2) INFORMATION FOR SEQ ID NO:46: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 20 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:46: 
TCCCCATATT. CTGGGGTTAC 
(2) INFORMATION FOR SEQ ID NO:47: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:47: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGT ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:48: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 48: 
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(2) INFORMATION FOR SEQ ID NO: 49: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:49: 
AGCCGGTAAC CCCAGAATAT GGGGAAATAC GCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:50: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:50: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGT. TCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:51: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:51: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGT CCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:52: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:52: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGC ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:53: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:53: 
AGCCGGTAAC CCCAGAATAT GGGGAAATTT CCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:54: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:54: 
AGCCGGTAAC CCCAGAATAT GGGGAAATCT, GCCCGATGTA GTCTAG 
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(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:55: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGC CCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:56: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:56: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGT, GCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:57: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:57: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGA TCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:58: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:58: 
AGCCGGTAAC CCCAGAATAT GGGGAAATCA. GCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO:59: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:59: 
AGCCGGTAAC CCCAGAATAT GGGGAAATTT TCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 60: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 60: 
AGCCGGTAAC CCCAGAATAT GGGGAAATCA TCCCGATGTA GTCTAG 
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(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 61: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGA, ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 62: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 62: 
AGCCGGTAAC CCCAGAATAT GGGGAAATCG GCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 63: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 63: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGG ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 64 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 64: 
AGCCGGTAAC CCCAGAATAT GGGGAAATGG TCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 65 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 65 : 
AGCCGGTAAC CCCAGAATAT GGGGAAATCC ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 66: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 66: 
AGCCGGTAAC CCCAGAATAT GGGGAAATAA CCCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 67: 
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(A) LENGTH: 46 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 67: 
AGCCGGTAAC CCCAGAATAT GGGGATCATC ACCCGATGTA GTCTAG 
(2) INFORMATION FOR SEQ ID NO: 68: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 23 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 68: 
GGATTATTGG GGTCATGGTG CTA 
(2) INFORMATION FOR SEQ ID NO: 69: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 69: 
AGCACCATGA CCCCAATAAT CCATGGCTGC TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 70 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 70 : 
AGCACCATGA CCCCAATAAT CCATGGCACG TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 71: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 71: 
AGCACCATGA CCCCAATAAT CCATGGCGTT TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 72: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 72: 
AGCACCATGA CCCCAATAAT CCATGGCGTC TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 73: 
(i) SEQUENCE CHARACTERISTICS: 
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(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 73: 
AGCACCATGA CCCCAATAAT CCATGGCGCA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 74: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 74: 
AGCACCATGA CCCCAATAAT CCATGGCTTC TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 75: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 75: 
AGCACCATGA CCCCAATAAT CCATGGCCTG TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 76 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 76 : 
AGCACCATGA CCCCAATAAT CCATGGCGCC TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 77: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 77: 
AGCACCATGA CCCCAATAAT CCATGGCGTG TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 78: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 78: 
AGCACCATGA CCCCAATAAT CCATGGCGAT TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 79: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
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(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 79: 
AGCACCATGA CCCCAATAAT CCATGGCCAG TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 80: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 80: 
AGCACCATGA CCCCAATAAT CCATGGCTTT TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 81: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 81: 
AGCACCATGA CCCCAATAAT CCATGGCCAT TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 82: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 82: 
AGCACCATGA CCCCAATAAT CCATGGCGAA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 83: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 83: 
AGCACCATGA CCCCAATAAT CCATGGCCGG TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 84: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 84: 
AGCACCATGA CCCCAATAAT CCATGGCGGA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 85: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
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(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:85: 
AGCACCATGA CCCCAATAAT CCATGGCGGT TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 86: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 86: 
AGCACCATGA CCCCAATAAT CCATGGCCCA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 87: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 87: 
AGCACCATGA CCCCAATAAT CCATGGCGTA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 88: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 88: 
AGCACCATGA CCCCAATAAT CCATGGCAAC TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 89: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 39 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 89: 
AGCACCATGA CCCCAATAAT CCATTCATCA TTTGTTACC 
(2) INFORMATION FOR SEQ ID NO: 90 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 90 : 
GCGTAGTTTG GCTACAGT 
(2) INFORMATION FOR SEQ ID NO: 91: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
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(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 91: 
AGCCAAACTA CGCATGTTCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 92: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 





(D) TOPOLOGY linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 92: 
AGCCAAACTA. CGCATGCACC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 93: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 





(D) TOPOLOGY linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 93: 
AGCCAAACTA. CGCATCGTCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 94 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(B) 
(D) TOPOLOGY linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 94 : 
AGCCAAACTA. CGCATAACCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 95 : 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 





(D) TOPOLOGY linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 95 : 
AGCCAAACTA. CGCATGACCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 96: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 





(D) TOPOLOGY linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 96: 
AGCCAAACTA. CGCATTGCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 97: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 
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(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 97: 
AGCCAAACTA. CGCATGAACC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 98: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 98: 
AGCCAAACTA. CGCATCAGCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 99: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 99: 
AGCCAAACTA. CGCATGGCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 100: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 100: 
AGCCAAACTA. CGCATCACCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 101: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 101: 
AGCCAAACTA. CGCATATCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 102: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 102: 
AGCCAAACTA. CGCATCTGCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 103: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
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AGCCAAACTA. CGCATAAACC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 104: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 104: 
AGCCAAACTA. CGCATATGCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 105: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 105: 
AGCCAAACTA CGCATTTCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 106: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO:106: 
AGCCAAACTA. CGCATCCGCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 107: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 107: 
AGCCAAACTA CGCATTCCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 108: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 108: 
AGCCAAACTA. CGCATACCCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 109: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
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AGCCAAACTA. CGCATTGGCC ACCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 110: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 110: 
AGCCAAACTA. CGCATTGACC ATGAACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 111: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 111: 
AGCCAAACTA. CGCATGTTCC AGCAACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 112: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 112: 
AGCCAAACTA CGCATGTTCC ACGTACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 113: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 113: 
AGCCAAACTA. CGCATGTTCC AAACACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 114 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 114 : 
AGCCAAACTA. CGCATGTTCC AGACACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 115: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 115: 










(2) INFORMATION FOR SEQ 
(i) SEQUENCE CHARAC 
(A) LENGTH: 31 
(B) TYPE: nucl 
(C) STRANDEDNE 
(D) TOPOLOGY: 
(xi). SEQUENCE DESCRI 
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PTION: SEQ ID NO : 116: 
AGCCAAACTA. CGCATGTTCC AGAAACGTTC G 
(2) INFORMATION FOR SEQ ID NO 117 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 







(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 117: 
AGCCAAACTA. CGCATGTTCC ACAGACGTTC G 
(2) INFORMATION FOR SEQ ID NO 118 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 118: 
AGCCAAACTA. CGCATGTTCC AGGCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 119 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 30 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 119 : 
AGCCAAACTA CGCATGTTCC ACACCGTTCG 
(2) INFORMATION FOR SEQ D NO 120 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: inear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 120 : 
AGCCAAACTA. CGCATGTTCC AA 
(2) INFORMATION FOR SEQ 
(i) SEQUENCE CHARAC) 
(A) LENGTH: 31 
CACGTTC G 
D NO 121 
ERISTICS 
base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: inear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 121: 








(2) INFORMATION FOR SEQ 
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ID NO 122 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 122: 
AGCCAAACTA. CGCATGTTCC AAAAACGTTC G 
(2) INFORMATION FOR SEQ D NO 123 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: inear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 123: 
AGCCAAACTA. CGCATGTTCC AATGACGTTC G 
(2) INFORMATION FOR SEQ D NO.124 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: inear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 124: 
AGCCAAACTA CGCATGTTCC ATTCACGTTC G 
(2) INFORMATION FOR SEQ 
(i) SEQUENCE CHARAC) 
D NO 125 
ERISTICS 
LENGTH: 31 base pairs 
STRANDEDNESS: single 
(A) 
(B) TYPE: nucleic acid 
(C) 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 125: 
AGCCAAACTA CGCATGTTCC ATCCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 126: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 
STRANDEDNESS: single 
(A) 
(B) TYPE: nucleic acid 
(C) 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 126: 
AGCCAAACTA. CGCATGTTCC AACCACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 127: 
(i) SEQUENCE CHARACTERISTICS: 
LENGTH: 31 base pairs 
STRANDEDNESS: single 
(A) 
(B) TYPE: nucleic acid 
(C) 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 127: 
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(2) INFORMATION FOR SEQ ID NO: 128: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 128: 
AGCCAAACTA CGCATGTTCC ATACACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 129: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 31 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 129: 
AGCCAAACTA CGCATGTTCC AGTTACGTTC G 
(2) INFORMATION FOR SEQ ID NO: 130: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 130: 
CGATGCGTCC GGCGTAGA 
(2) INFORMATION FOR SEQ ID NO: 131: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 19 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 131: 
GCTAGTTATT GCTCAGCGG 
(2) INFORMATION FOR SEQ ID NO: 132: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 269 amino acids 
(B) TYPE: amino acid 
(C) STRANDEDNESS: 
(D) TOPOLOGY: linear 
(xi). SEQUENCE DESCRIPTION: SEQ ID NO : 132: 
Met Glu Val Glin Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly 
1 5 10 15 
Ala Ser Val Arg Met Ser Cys Lys Ser Ser Gly Tyr Ile Phe Thr Asp 
2O 25 30 
Phe Tyr Met Asn Trp Val Arg Glin Ser His Gly Lys Ser Leu Asp Tyr 
35 40 45 
Ile Gly Tyr Ile Ser Pro Tyr Ser Gly Val Thr Gly Tyr Asin Gln Lys 
50 55 60 
Phe Lys Gly Lys Ala Thr Lieu. Thr Val Asp Llys Ser Ser Ser Thr Ala 
65 70 75 8O 
Tyr Met Glu Leu Arg Ser Leu Thir Ser Glu Asp Ser Ala Val Tyr Tyr 
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Ala Ser Ser Asn Ala Met 
100 
Gly Gly Trp 
105 
Asp Tyr 






Gly Gly Gly Gly 
Ile Wall Thr 
1 4 0 




Gly Gly Gly Gly Asp 
Wall Glin Ala Thr 
155 
Teu Ile Ser 
15 O 
Ser Lieu Pro Ser 
145 
Gly Asp 
Asn Thr Teu 
170 
Glin Wal His Ser Asn 
1.65 
Ser Ser Lieu Gly 
Glin Ala 
18O 







Phe Ser Asn Arg Ser Gly Pro Arg Ser Gly 
Phe Thr Thir Ile 
215 
Wall Glu Glu 
220 
Ser Asp Teu 
210 
Asp Arg Asp 






Cys Ser Thir Thr 
Thr Glu 
245 
Gly Ile Ile Ala Ser Glin Pro Glu 
250 
Telu 
His His His His His 
265 
Glu Glu His 
260 
Asp Pro Asp Val Glu 
What is claimed: 
1. A method of identifying an antibody variant comprising 
the Steps of: 
a) providing a DNA segment encoding a antibody, or 
antigen-binding fragment thereof; 
b) providing a set of primers that encode all nineteen 
naturally-occurring amino acid variants at a Single 
residue of Said antibody or antigen-binding fragment 
thereof; 
c) performing PCR reactions on said DNA segment, using 
Said Set of primers, to generate a set of variant DNA 
Segments encoding nineteen amino acid Substitution 
variants at Said Single residue of Said antibody or 
antigen binding fragment thereof; 
d) expressing each of Said Substitution variants using in 
Vitro transcription/translation; 
e) identifying said antibody variant by increased antigen 
binding Specificity. 
2. The method of claim 1, wherein said transcription/ 
translation employs a prokaryotic expression System. 
3. The method of claim 1, wherein said gene is under the 
transcriptional control of a phage promoter. 
4. The method of claim 3, wherein said promoter is T7, 
trc, tac, lipp-lac, trp, tet, lac, PBAD, phoA or P. 
5. The method of claim 1, wherein said antigen binding 
activity is assessed by ELISA. 
6. The method of claim 1, wherein said DNA segment 
encodes a single-chain antibody. 
7. The method of claim 1, wherein said primers are 
between about 10 and about 50 bases in length. 
8. The method of claim 1, wherein said antibody is a 
catalytic antibody, and Said antibody variant further is iden 



































9. A method of identifying an antibody variant comprising 
the Steps of: 
a) providing a DNA segment encoding a antibody, or 
antigen-binding fragment thereof; 
b) providing a set of primers that encode all naturally 
occurring nineteen amino acid variants at a Single 
residue of Said antibody or antigen-binding fragment 
thereof; 
c) performing PCR reactions on said DNA segment, using 
Said Set of primers, to generate a set of variant DNA 
Segments encoding nineteen amino acid Substitution 
Variants at Said Single residue of Said antibody or 
antigen binding fragments thereof; 
d) repeating Steps b and c at a second residue of Said 
antibody or antigen binding fragment thereof; 
e) expressing each of Said Substitution variants using in 
Vitro transcription/translation; and 
f) identifying said antibody variant by increased antigen 
binding affinity. 
10. The method of claim 9, wherein said transcription/ 
translation employs a prokaryotic expression System. 
11. The method of claim 9, wherein said gene is under the 
transcriptional control of a phage promoter. 
12. The method of claim 11, wherein said promoter is T7, 
trc, tac, lpp-lac, trp, tet, lac, PBAD, phoA or P. 
13. The method of claim 9, wherein said antigen binding 
activity is assessed by ELISA. 
14. The method of claim 9, wherein said DNA segment 
encodes a single-chain antibody. 
15. The method of claim 9 wherein primers are between 
about 10 and about 50 bases in length. 
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16. The method of claim 9 wherein said antibody variant 
or antigen binding fragment thereof exhibits a lesser degree 
of croSS-reactivity with related antigen species than does 
Said antibody. 
17. The method of claim 9, wherein said antibody is a 
catalytic antibody, and Said antibody variant further is 
defined by means of enzymatic activity. 
18. The method of claim 9, wherein steps b and c are 
repeated a Second time. 
94 
19. The method of claim 18, wherein steps b and c are 
repeated a third time. 
20. The method of claim 19, wherein steps b and c are 
5 repeated a fourth time. 
21. The method of claim 20, wherein steps b and c arc 
repeated a fifth time. 
